[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1551
1. Jha P, Agarwal S, Pathak P, Srivastava A, Suri V, Sharma MC, Chosdol K, Srivastava T, Gupta D, Gupta A, Suri A, Sarkar C: Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. Cancer Genet Cytogenet; 2010 Apr 15;198(2):126-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
  • There are few reports of loss of heterozygosity (LOH) of 1p and 19q in astrocytic tumors, especially glioblastoma multiforme (GBM).
  • Thus, 1p and 19q LOH can occur in astrocytic tumors, most commonly in secondary GBMs without morphological correlation with an oligodendroglial histology.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Gene Amplification. Genes, erbB-1. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Child. Female. Heterozygote. Humans. India. Loss of Heterozygosity. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20362227.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


2. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol; 2010 Nov 01;28(31):4722-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
  • PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity.
  • Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms.
  • Intradermal vaccinations were given until toxicity or tumor progression was observed.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / immunology. Cancer Vaccines / immunology. Cancer Vaccines / therapeutic use. Glioblastoma / drug therapy. Glioblastoma / immunology. Receptor, Epidermal Growth Factor / immunology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Adjuvant. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Disease-Free Survival. Drug Administration Schedule. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Injections, Intradermal. Magnetic Resonance Imaging. Male. Middle Aged. Mutation. Predictive Value of Tests. Prognosis. Prospective Studies. Radiotherapy, Adjuvant. Sample Size. Time Factors. Tumor Suppressor Proteins / genetics. United States

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4247-54 [14519652.001]
  • [Cites] J Immunol Methods. 2008 Nov 30;339(1):74-81 [18775433.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5955-64 [18632651.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3335-9 [12067969.001]
  • [Cites] Mol Cell Neurosci. 2003 Dec;24(4):1116-30 [14697673.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Radiother Oncol. 2004 Sep;72(3):267-73 [15450724.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1656-62 [15477864.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4207-11 [1693434.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Ann Neurol. 1990 Dec;28(6):818-22 [2178330.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3140-8 [7606735.001]
  • [Cites] Cell Growth Differ. 1995 Oct;6(10):1251-9 [8845302.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):5079-86 [8895767.001]
  • [Cites] Biochem J. 1997 Jun 15;324 ( Pt 3):855-61 [9210410.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):6472-80 [15528389.001]
  • [Cites] J Immunother. 2004 Nov-Dec;27(6):452-9 [15534489.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1462-6 [15746047.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5064-73 [16951222.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2288-94 [17538175.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3098-104 [18483377.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17358-63 [10749863.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):842-7 [11221866.001]
  • [Cites] Neurosurgery. 2002 Jan;50(1):158-64; discussion 164-6 [11844246.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):357-61 [11920586.001]
  • [CommentIn] J Clin Oncol. 2010 Nov 1;28(31):4670-3 [20921460.001]
  • [CommentIn] J Clin Oncol. 2011 Aug 1;29(22):3105; author reply 3105-6 [21709193.001]
  • [CommentIn] J Clin Oncol. 2011 Jun 10;29(17):e517-8; author reply e519-20 [21555685.001]
  • [CommentIn] Nat Rev Clin Oncol. 2011 Jan;8(1):4 [21218529.001]
  • (PMID = 20921459.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120813; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R01 CA097222; United States / NINDS NIH HHS / NS / 5P50 NS20023; United States / NCI NIH HHS / CA / R01-CA97222-05; United States / NCI NIH HHS / CA / 5P50 CA108786; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cancer Vaccines; 0 / Tumor Suppressor Proteins; 0 / epidermal growth factor receptor VIII; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ PMC3020702
  •  go-up   go-down


3. van Vuurden DG, Yazdani M, Bosma I, Broekhuizen AJ, Postma TJ, Heimans JJ, van der Valk P, Aronica E, Tannous BA, Würdinger T, Kaspers GJ, Cloos J: Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment. PLoS One; 2009;4(6):e5953
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment.
  • BACKGROUND: Glioblastoma multiforme (GBM) cells secrete large amounts of glutamate that can trigger AMPA-type glutamate receptors (AMPARs).
  • METHODS AND FINDINGS: In silico analysis of published reports shows down-regulation of all ionotropic glutamate receptors in GBM as compared to normal brain.
  • In vitro, in all GBM samples tested, mRNA expression of AMPAR subunit GluR1, 2 and 4 was relatively low compared to adult and fetal total brain mRNA and adult cerebellum mRNA.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Glioblastoma / metabolism. Glioblastoma / pathology. Glutamic Acid / metabolism. Receptors, AMPA / biosynthesis
  • [MeSH-minor] Animals. Brain / pathology. Calcium / chemistry. Cell Line, Tumor. Cell Proliferation. Cell Survival. Humans. Immunohistochemistry / methods. Mice. Sodium / chemistry

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. SODIUM .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2008 Jun 11;582(13):1847-52 [18474242.001]
  • [Cites] Mol Pharmacol. 2008 May;73(5):1444-53 [18094072.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10767-77 [10594060.001]
  • [Cites] Brain Res. 2000 Dec 15;886(1-2):190-207 [11119696.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1010-5 [11533703.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Nat Med. 2002 Sep;8(9):971-8 [12172541.001]
  • [Cites] Nat Med. 2002 Sep;8(9):938-40 [12205454.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] J Child Neurol. 2004 May;19(5):343-60; discussion 361 [15224708.001]
  • [Cites] Life Sci. 2004 Jul 30;75(11):1313-22 [15234189.001]
  • [Cites] Cancer Res. 1992 Jan 1;52(1):108-16 [1727369.001]
  • [Cites] J Physiol. 1992 Dec;458:261-87 [1338788.001]
  • [Cites] J Neurosci Res. 1996 Oct 15;46(2):164-78 [8915893.001]
  • [Cites] Eur J Neurosci. 1998 Jun;10(6):2153-62 [9753101.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] J Neurosci. 2005 Aug 3;25(31):7101-10 [16079392.001]
  • [Cites] Glia. 2006 Jan 15;53(2):212-24 [16206168.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] J Neurochem. 2006 Jun;97(6):1611-26 [16805772.001]
  • [Cites] Med Res Rev. 2007 Mar;27(2):239-78 [16892196.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosci. 2007 Jul 25;27(30):7987-8001 [17652589.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93 [17971532.001]
  • [Cites] J Neurosci. 2008 Aug 27;28(35):8740-6 [18753375.001]
  • (PMID = 19536293.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, AMPA; 3KX376GY7L / Glutamic Acid; 9NEZ333N27 / Sodium; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2693929
  •  go-up   go-down


Advertisement
4. Mulholland PJ, Fiegler H, Mazzanti C, Gorman P, Sasieni P, Adams J, Jones TA, Babbage JW, Vatcheva R, Ichimura K, East P, Poullikas C, Collins VP, Carter NP, Tomlinson IP, Sheer D: Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle; 2006 Apr;5(7):783-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme.
  • Glioblastoma multiforme is the most common tumor arising in the central nervous system.
  • In this study, we identify copy number changes in a series of glioblastoma multiforme tumors and cell lines by applying high-resolution microarray comparative genomic hybridization.
  • [MeSH-major] Chromosome Deletion. Gene Expression Profiling. Genome, Human / genetics. Glioblastoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Chromosomes, Human, Pair 6 / genetics. Chromosomes, Human, Pair 7 / genetics. Cytogenetics. Female. Gene Dosage / genetics. Gene Expression. Genomics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Nucleic Acid Hybridization

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16582634.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A3585; United Kingdom / Cancer Research UK / / A6618
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD: Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med; 2008 Jan;49(1):30-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
  • alpha-Particle-emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system.
  • Because of the much shorter range and more potent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled agents may be ideal for the eradication of tumor cells remaining after surgical debulking of malignant brain tumors.
  • The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors.
  • Six patients experienced grade 2 neurotoxicity within 6 wk of (211)At-ch81C6 administration; this neurotoxicity resolved fully in all but 1 patient.
  • No toxicities of grade 3 or higher were attributable to the treatment.
  • The median survival times for all patients, those with glioblastoma multiforme, and those with anaplastic astrocytoma or oligodendroglioma were 54, 52, and 116 wk, respectively.
  • Specifically, the regional administration of (211)At-ch81C6 is feasible, safe, and associated with a promising antitumor benefit in patients with malignant central nervous system tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 1997 May;20(3):214-43 [9181460.001]
  • [Cites] Appl Radiat Isot. 1996 Feb;47(2):135-43 [8852627.001]
  • [Cites] Radiat Res. 1998 Feb;149(2):155-62 [9457895.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2202-12 [9626222.001]
  • [Cites] Nucl Med Biol. 1998 May;25(4):351-7 [9639296.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1933-40 [9731050.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2495-502 [9796983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):491-9 [10487576.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S [15653670.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1042-51 [15937318.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4451-9 [15958630.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1393-400 [16085599.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):115-22 [16382120.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):912-8 [16741299.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3275s-3280s [10541375.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Curr Pharm Des. 2000 Sep;6(14):1433-55 [10903402.001]
  • [Cites] J Nucl Med. 2001 Oct;42(10):1508-15 [11585865.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1233-9 [12149203.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1259-75 [12419456.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1767-73 [3667382.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2807-13 [2469537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):55-7 [1512163.001]
  • [Cites] Invest Radiol. 1993 Jun;28(6):488-96 [7686539.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Nucl Med Biol. 1996 May;23(4):449-58 [8832699.001]
  • [Cites] Nucl Med Biol. 1997 Apr;24(3):255-61 [9228660.001]
  • (PMID = 18077533.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / NS20023; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R01 CA042324; United States / NINDS NIH HHS / NS / P50 NS020023-268624; United States / NCI NIH HHS / CA / CA014236-35S59008; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA42324; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR30; United States / NINDS NIH HHS / NS / NS020023-268624; United States / NCI NIH HHS / CA / R37 CA042324; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / R37 CA042324-23; United States / NCI NIH HHS / CA / P30 CA014236-35S59008; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Tenascin; XI595HAL7H / Astatine
  • [Other-IDs] NLM/ NIHMS180689; NLM/ PMC2832604
  •  go-up   go-down


6. Samaras V, Stamatelli A, Samaras E, Arnaoutoglou C, Arnaoutoglou M, Stergiou I, Konstantopoulou P, Varsos V, Karameris A, Barbatis C: Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features. Pathol Res Pract; 2009;205(11):765-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lower aurora-A immunohistochemical expression, chemotherapy administration, and tumor localization in one lobe of the brain implied a greater probability of patient survival in univariate analysis (p=0.044, p=0.008, p=0.041, respectively).
  • [MeSH-major] Brain Neoplasms / metabolism. Cell Proliferation. Cerebral Cortex / metabolism. Glioblastoma / metabolism. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / metabolism. Male. Middle Aged. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19616898.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


7. Nathoo N, Prayson RA, Bondar J, Vargo L, Arrigain S, Mascha EJ, Suh JH, Barnett GH, Golubic M: Increased expression of 5-lipoxygenase in high-grade astrocytomas. Neurosurgery; 2006 Feb;58(2):347-54; discussion 347-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of 5-lipoxygenase in high-grade astrocytomas.
  • METHODS: Increased 5-LO messenger ribonucleic acid and protein expression was detected by the polymerase chain reaction and antibody-based approaches, respectively, in surgical astrocytoma specimens and established glioblastoma multiforme cell lines compared with primary cell culture from the human white matter.
  • RESULTS: Immunohistochemical analysis revealed predominantly nuclear 5-LO staining in 44 of 49 glioblastoma multiforme samples (90%), 8 of 10 (80%) anaplastic astrocytomas samples, and 3 of 13 (23%) low-grade astrocytoma samples analyzed.
  • Double-staining experiments with anti-CD-68 (macrophage/microglial marker) and anti-5-LO antibodies suggest that both CD-68-positive and CD-68-negative tumor cells express 5-LO protein.
  • Staining of 5-LO was significantly more frequent in high-grade than in low-grade tumors (P = 0.001).
  • CONCLUSION: These data indicate that 5-LO is overexpressed in high-grade astrocytomas and supports the idea that eicosanoids may play a role in tumorigenesis of these brain tumors.
  • [MeSH-major] Arachidonate 5-Lipoxygenase / biosynthesis. Astrocytoma / enzymology. Brain Neoplasms / enzymology. Gene Expression Regulation, Neoplastic / physiology
  • [MeSH-minor] Adult. Aged. Brain / cytology. Brain / enzymology. Cells, Cultured. HL-60 Cells. Humans. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retrospective Studies. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462489.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 107277
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  •  go-up   go-down


8. Nishikawa R: [Recent advances in the medical treatment of glioma-temozolomide]. No To Shinkei; 2006 Dec;58(12):1035-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Administration Schedule. Female. Glioblastoma / drug therapy. Glioblastoma / mortality. Glioblastoma / radiotherapy. Humans. Male. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17193953.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


9. Sie M, de Bont ES, Scherpen FJ, Hoving EW, den Dunnen WF: Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma? Neuropathol Appl Neurobiol; 2010 Dec;36(7):636-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma?
  • AIMS: Pilocytic astrocytomas are the most frequent brain tumours in children.
  • In this study 59 paediatric pilocytic astrocytomas were compared with 62 adult glioblastomas, as a prototype of tumour angiogenesis.
  • METHODS: Microvessel density, vessel maturity in terms of basement membrane and pericyte coverage, and turnover of both endothelial and tumour cells, and vascular endothelial growth factor (VEGF) expression were evaluated in tumour tissue, immunohistochemically stained with, respectively, CD34, collagen IV, smooth muscle actin, Ki67/CD34, caspase-3/CD34 and VEGF(-A-D).
  • RESULTS: Pilocytic astrocytoma and glioblastoma showed similar fractions of vessels covered with basement membrane and pericytes.
  • Pilocytic astrocytoma had fewer but wider vessels compared with glioblastoma.
  • Turnover of endothelial and tumour cells were relatively lower in pilocytic astrocytoma.
  • Within pilocytic astrocytoma, higher ANGPT-1/ANGPT-2 balance was correlated with fewer apoptotic endothelial cells.
  • CONCLUSIONS: Despite the fact that pilocytic astrocytoma showed a different vessel architecture compared with glioblastoma, a critical overlap in vessel immaturity/instability and the angiogenic profile was seen between both tumours.
  • These findings suggest encouraging possibilities for targeting angiogenesis (for instance with anti-VEGF) as a therapeutic strategy in pilocytic astrocytoma.
  • [MeSH-major] Brain Neoplasms / blood supply. Brain Neoplasms / pathology. Glioblastoma / blood supply. Glioblastoma / pathology. Neovascularization, Pathologic / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Neuropathology and Applied Neurobiology © 2010 British Neuropathological Society.
  • (PMID = 20704656.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


10. Martinez R, Rohde V, Schackert G: Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol; 2010 Feb;96(3):321-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.
  • One of the hallmarks of glioblastoma is its inherent tendency to recur.
  • In all tumor samples, we have analyzed p53 and PTEN status by sequencing analysis, EGFR amplification by semiquantitative PCR and a wide-genome fingerprinting was performed by microsatellite analysis.
  • Upon recurrence, we have detected two molecular patterns of tumor progression: GBM initially showing either type 1 or type 2 profiles conserved them at the time of relapse.
  • Taken together, our results strongly suggest that recurrences of GBM may display two distinct pattern of accumulation of molecular alterations depending on the profile of the original tumor.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Glioblastoma / genetics. Mutation / genetics. PTEN Phosphohydrolase / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Am J Hum Genet. 2006 Nov;79(5):923-34 [17033968.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):960-9 [17342095.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1264-8 [17272309.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):71-8 [18004504.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):934-41 [10551321.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] Hum Mutat. 2000;16(2):109-22 [10923032.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1037-42 [11045785.001]
  • [Cites] Mol Carcinog. 2000 Nov;29(3):143-50 [11108659.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):255-7 [11300334.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jan 1;132(1):20-4 [11801303.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):681-90 [11983757.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):779-83 [12754350.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):82-90 [12784873.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1954-6 [14647431.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 May;75(5):723-6 [15090567.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6806-14 [15286718.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):432-7 [1324297.001]
  • [Cites] Hum Genet. 1994 May;93(5):607-8 [8168846.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):813-8 [7947085.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):57-64 [7815080.001]
  • [Cites] J Neurooncol. 1994;21(2):151-7 [7861191.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):661-4 [8760309.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1385-90 [10022821.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 19644652.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2811648
  •  go-up   go-down


11. Scrideli CA, Carlotti CG Jr, Okamoto OK, Andrade VS, Cortez MA, Motta FJ, Lucio-Eterovic AK, Neder L, Rosemberg S, Oba-Shinjo SM, Marie SK, Tone LG: Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol; 2008 Jul;88(3):281-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR.
  • We have used this approach to identify differentially expressed genes between primary glioblastomas and non-neoplastic brain tissues.
  • We selected 20 overexpressed genes related to cell cycle, cellular movement and growth, proliferation and cell-to-cell signaling and analyzed their expression levels by real time quantitative PCR in cDNA obtained from microdissected fresh tumor tissue from 20 patients with primary glioblastomas and from 10 samples of non-neoplastic white matter tissue.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression. Glioblastoma / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Brain / physiology. Gene Expression Profiling. Humans. Immunohistochemistry. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):44-53 [11668477.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Oct;32(5):461-8 [16972880.001]
  • [Cites] Biochim Biophys Acta. 2004 Dec 17;1705(2):121-32 [15588766.001]
  • [Cites] Cell. 1994 Dec 16;79(6):1121 [8001138.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11709-17 [17178866.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2680-8 [12730682.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):233-9 [17285230.001]
  • [Cites] J Cell Physiol. 2007 Apr;211(1):19-26 [17167774.001]
  • [Cites] Acta Neuropathol. 2006 May;111(5):483-8 [16596424.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):301-5 [12053177.001]
  • [Cites] J Neurooncol. 2006 Aug;79(1):19-30 [16807783.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):493-9 [16411134.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14 (22):3449-61 [16207734.001]
  • [Cites] Acta Neuropathol. 1999 May;97(5):481-90 [10334485.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7344-53 [16243806.001]
  • [Cites] Am J Clin Pathol. 2007 Apr;127(4):585-90 [17369134.001]
  • [Cites] Mol Cancer Res. 2005 Dec;3(12):645-53 [16380502.001]
  • [Cites] Oncogene. 1998 Aug 27;17(8):1019-26 [9747881.001]
  • [Cites] Apoptosis. 2003 Jun;8(3):229-36 [12766483.001]
  • [Cites] Cell. 2003 Oct 31;115(3):293-303 [14636557.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12 ):1816-22 [16773075.001]
  • [Cites] BMC Genomics. 2006 Oct 20;7:268 [17054779.001]
  • [Cites] EMBO J. 2004 Aug 18;23(16):3216-26 [15272311.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7821-9 [16027728.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):662-77 [17060456.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1065-70 [12671706.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):563-9 [16804930.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9543-56 [17018611.001]
  • [Cites] J Histochem Cytochem. 2005 Aug;53(8):997-1002 [15923371.001]
  • [Cites] Neuro Oncol. 2000 Jul;2(3):164-73 [11302337.001]
  • [Cites] Acta Neuropathol. 2006 May;111(5):465-74 [16557391.001]
  • [Cites] Cell Growth Differ. 1995 Mar;6(3):219-27 [7794790.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):521-31 [16865252.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2461-9 [16353136.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):644-51 [10468852.001]
  • [Cites] J Urol. 2005 May;173(5):1496-501 [15821467.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2397-409 [16951254.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Feb;26(1):67-75 [10736068.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5464-71 [15328185.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):305-12 [14719106.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] BMC Cancer. 2005 Sep 12;5:113 [16156888.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1276-84 [16615118.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 6;305(3):598-604 [12763036.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 23;354(4):913-8 [17276395.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14 ):8342-7 [12829790.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Int J Oncol. 2006 Dec;29(6):1337-47 [17088971.001]
  • [Cites] Biochim Biophys Acta. 2004 Nov 29;1695(1-3):45-54 [15571808.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3589-97 [11313484.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):947-50 [17187361.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jan;126(1):42-8 [11800646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Cancer Lett. 2001 Apr 10;165(1):1-10 [11248412.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Mar;21(3):195-206 [9523194.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):875-83 [11035016.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Drug Discov Today. 2005 May 15;10(10):727-34 [15896686.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):1-5 [17179989.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):267-78 [15175080.001]
  • [Cites] Dev Genes Evol. 2002 Apr;212(3):107-13 [11976948.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4493-7 [9377559.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Neoplasia. 2006 Nov;8(11):925-32 [17132224.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6698-706 [8943324.001]
  • [Cites] Neuron. 2006 Dec 21;52(6):953-68 [17178400.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):181-91 [15013523.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 May;132(5):302-8 [16416108.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12 (18):5395-402 [17000672.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):133-43 [12744467.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):4983-6 [16707416.001]
  • (PMID = 18398573.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Grahovac G, Tomac D, Lambasa S, Zoric A, Habek M: Cerebellar glioblastomas: pathophysiology, clinical presentation and management. Acta Neurochir (Wien); 2009 Jun;151(6):653-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme usually affects the cerebral hemispheres with the peak age of onset in the sixth or seventh decade, while cerebellar glioblastoma multiforme is a rare tumour especially in younger patients.
  • Most result from de-differentiation from low grade astrocytoma (secondary glioblastoma) or can develop de novo (primary glioblastoma).
  • We report a 28 year old patient with primary multi-focal cerebellar glioblastoma multiforme and review the pathophysiology, clinical presentation, diagnosis and treatment of cerebellar glioblastomas.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Genetic Predisposition to Disease / genetics. Glioblastoma / pathology. Mutation / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cerebellum / pathology. Cerebellum / radiography. Cerebellum / surgery. Fatal Outcome. Female. Fourth Ventricle / pathology. Fourth Ventricle / surgery. Headache / etiology. Humans. Hydrocephalus / etiology. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Reoperation. Tomography, X-Ray Computed. Vomiting / etiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319469.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


13. Ducray F, Colin P, Cartalat-Carel S, Pelissou-Guyotat I, Mahla K, Audra P, Gaucherand P, Honnorat J, Trouillas P: [Management of malignant gliomas diagnosed during pregnancy]. Rev Neurol (Paris); 2006 Mar;162(3):322-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology revealed a glioblastoma multiforme.
  • Histology revealed a glioblastoma multiforme.
  • The last patient received combined treatment with radiotherapy and chemotherapy for local recurrence of a mesencephalic high-grade glioma.
  • Generally speaking, surgical resection of high-grade gliomas should not be delayed during pregnancy.
  • [MeSH-major] Case Management. Glioblastoma / therapy. Pregnancy Complications, Neoplastic / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Abortion, Therapeutic. Adrenal Cortex Hormones / therapeutic use. Adult. Algorithms. Anesthesia, General. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carbamazepine / therapeutic use. Carmustine / administration & dosage. Cesarean Section. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Frontal Lobe. Humans. Infant, Newborn. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Paresis / drug therapy. Paresis / etiology. Prednisolone / therapeutic use. Pregnancy. Prenatal Exposure Delayed Effects. Radiotherapy, Adjuvant. Remission Induction. Temporal Lobe

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. Fotemustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Neurol (Paris). 2006 Mar;162(3):293-4 [16585883.001]
  • (PMID = 16585887.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 33CM23913M / Carbamazepine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9PHQ9Y1OLM / Prednisolone; GQ7JL9P5I2 / fotemustine; U68WG3173Y / Carmustine
  •  go-up   go-down


14. Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F, Jones C, Reis RM: Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res; 2008 Mar-Apr;28(2A):913-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioma / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Female. Gene Amplification. Glioblastoma / genetics. Humans. Male. Middle Aged. Mutation. Oligodendroglioma / genetics. Portugal. Prognosis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507036.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / epidermal growth factor receptor VIII; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


15. Pennington C, Kilbride L, Grant R, Wardlaw JM: A pilot study of brain tumour growth between radiotherapy planning and delivery. Clin Oncol (R Coll Radiol); 2006 Mar;18(2):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of brain tumour growth between radiotherapy planning and delivery.
  • AIMS: Delays between surgery and the delivery of radiotherapy may allow brain tumours to grow beyond the planned radiotherapy fields and therefore reduce the effectiveness of radiotherapy.
  • This pilot study aimed to ascertain whether significant growth of brain tumours occurs between post-biopsy imaging and the start of radiotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioblastoma / pathology. Glioblastoma / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Pilot Projects. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523809.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Lucena Rde C, de Mello RJ, Lessa JR Jr, Cavalcante GM, Ribeiro M: [Clinical topographic findings in glioblastoma multiforme and the relation with motor impairment]. Arq Neuropsiquiatr; 2006 Jun;64(2B):441-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical topographic findings in glioblastoma multiforme and the relation with motor impairment].
  • Glioblastoma multiforme (GBM) is the glial tumor with the highest grade of malignity.
  • It mainly affects the cerebral hemispheres, presenting general or focal signs and symptoms, which depend on the size, the location of the lesion and rate of growth of the tumor.
  • RESULTS: The occurrence of the tumor was preponderant in adults (mean age 55 years old), men (55.82%), and frontal lobe (approximately 40%).
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Movement Disorders / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Movement Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917616.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


17. Kashimura H, Inoue T, Beppu T, Ogasawara K, Ogawa A: Diffusion tensor imaging for differentiation of recurrent brain tumor and radiation necrosis after radiotherapy--three case reports. Clin Neurol Neurosurg; 2007 Jan;109(1):106-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion tensor imaging for differentiation of recurrent brain tumor and radiation necrosis after radiotherapy--three case reports.
  • Fractional anisotropy (FA) is influenced by histological data such as cellularity, vascularity and/or fiber structure in astrocytic tumors.
  • We describe two patients with tumor recurrence and one patient with radiation necrosis who were diagnosed using assessment of FA value.
  • The assessment of FA value in enhanced lesions after radiotherapy may be able to differentiate radiation necrosis from tumor recurrence.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology. Radiation Injuries / pathology
  • [MeSH-minor] Adult. Aged. Anisotropy. Female. Humans. Middle Aged. Necrosis. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793199.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Parlato C, Barbarisi M, Moraci M, Moraci A: Surgery, radiotherapy and temozolomide in treating high-grade gliomas. Front Biosci; 2006;11:1280-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
  • Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas.
  • Twelve patients with newly diagnosed glioblastoma (GBM), and anaplastic astrocytoma (AA) were studied.
  • In two cases of glioblastoma, we observed complete response and after three years, the quality of life is optimal.
  • Temozolomide appears to be an ideal, first-line, single-agent, with a safe profile and demonstrated HQL benefits in patients with high-grade gliomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / therapy. Combined Modality Therapy / methods. Dacarbazine / analogs & derivatives. Glioma / therapy
  • [MeSH-minor] Adult. Astrocytoma / therapy. Clinical Trials as Topic. Disease Progression. Disease-Free Survival. Female. Glioblastoma / therapy. Humans. Male. Middle Aged. Quality of Life. Radiotherapy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16368514.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


19. Kong DS, Nam DH, Lee JI, Park K, Kim JH: Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme. J Neurosurg; 2006 Dec;105 Suppl:139-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme.
  • OBJECT: The authors conducted a retrospective study to evaluate the efficacy of Gamma Knife surgery (GKS) followed by radiotherapy for the treatment of unresectable glioblastomas multiforme (GBMs) on patient survival and quality of life.
  • METHODS: A total of 19 patients with unresectable GBMs located in eloquent areas of the brain were eligible for this study.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Glioblastoma / radiotherapy. Glioblastoma / surgery. Neoadjuvant Therapy. Quality of Life. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18503347.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Pisati F, Belicchi M, Acerbi F, Marchesi C, Giussani C, Gavina M, Javerzat S, Hagedorn M, Carrabba G, Lucini V, Gaini SM, Bresolin N, Bello L, Bikfalvi A, Torrente Y: Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Cancer Res; 2007 Apr 1;67(7):3054-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
  • New experimental approaches have shown tumor regression after the grafting of neural stem cells and human mesenchymal stem cells into experimental intracranial gliomas of adult rodents.
  • However, the cell source seems to be an important limitation for autologous transplantation in glioblastoma.
  • In the present study, we evaluated the tumor targeting and antitumor activity of human skin-derived stem cells (hSDSCs) in human brain tumor models.
  • The hSDSCs exhibit tumor targeting characteristics in vivo when injected into the controlateral hemisphere or into the tail vein of mice.
  • When implanted directly into glioblastomas, hSDSCs distributed themselves extensively throughout the tumor mass, reduced tumor vessel density, and decreased angiogenic sprouts.
  • In addition, transplanted hSDSCs differentiate into pericyte cell and release high amounts of human transforming growth factor-beta1 with low expression of vascular endothelial growth factor, which may contribute to the decreased tumor cell invasion and number of tumor vessels.
  • In long-term experiments, the hSDSCs were also able to significantly inhibit tumor growth and to prolong animal survival.
  • Similar behavior was seen when hSDSCs were implanted into two different tumor models, the chicken embryo experimental glioma model and the transgenic Tyrp1-Tag mice.
  • Taken together, these data validate the use of hSDSCs for targeting human brain tumors.
  • [MeSH-major] Brain Neoplasms / blood supply. Brain Neoplasms / therapy. Glioblastoma / blood supply. Glioblastoma / therapy. Skin / cytology. Stem Cell Transplantation. Stem Cells / physiology
  • [MeSH-minor] Animals. Cell Growth Processes / physiology. Cell Line, Tumor. Chick Embryo. Chorioallantoic Membrane / blood supply. Humans. Mice. Mice, Nude. Mice, Transgenic. Neoplasm Invasiveness. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / therapy. Transforming Growth Factor beta1 / biosynthesis. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409412.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1
  •  go-up   go-down


21. Sungarian A, Cielo D, Sampath P, Bowling N, Moskal P, Wands JR, de la Monte SM: Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma. J Oncol; 2009;2009:302084
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.
  • Glioblastomas are high-grade, malignant CNS neoplasms that are nearly always fatal within 12 months of diagnosis.
  • Immunotherapy using proinflammatory cytokines such as IL-2 or IL-12 may prolong survival with glioblastoma.
  • We examined potential therapeutic effects of Talpha1 in experimental in vivo glioblastoma, and characterized Talpha1's anti-tumor effects in vitro.
  • Rar 9L cells (10(4)) were implanted into the right frontal lobe of adult Long Evans rats that were subsequently treated with vehicle, BCNU, Talpha1, or Talpha1+BCNU from postoperative day 6.
  • Talpha1+BCNU significantly lowered tumor burdens, and increased cure rates.
  • The findings suggest that Talpha1 enhances BCNUmediated eradication of glioblastoma in vivo, and that Talpha1 mediates its effects by activating pro-apoptosis mechanisms, rendering neoplastic cells more sensitive to oxidative stress and immune-mediated killing by Granzyme B and chemotherapeutic agents.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 1990 May;27(2-3):141-7 [2139665.001]
  • [Cites] Int J Immunopharmacol. 1989;11(7):789-800 [2599716.001]
  • [Cites] Biochim Biophys Acta. 2003 Mar 6;1557(1-3):109-17 [12615354.001]
  • [Cites] Biotechniques. 2002 Jul;33(1):98-100, 102, 104 passim [12139262.001]
  • [Cites] Lab Invest. 2002 Jul;82(7):881-91 [12118090.001]
  • [Cites] Curr Opin Investig Drugs. 2002 May;3(5):698-707 [12090542.001]
  • [Cites] J Viral Hepat. 2002 Jul;9(4):280-7 [12081605.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):798-802 [12063993.001]
  • [Cites] Int Rev Immunol. 2001 Jun;20(3-4):415-37 [11878511.001]
  • [Cites] Curr Pharm Des. 2002;8(11):959-66 [11945142.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Dec;15(12):1899-905 [11736720.001]
  • [Cites] Cell Mol Life Sci. 2001 Nov;58(12-13):1950-60 [11766890.001]
  • [Cites] Expert Opin Biol Ther. 2001 Jan;1(1):93-107 [11727550.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):3-12 [11550133.001]
  • [Cites] J Viral Hepat. 2001 May;8(3):194-201 [11380797.001]
  • [Cites] Cell Death Differ. 2000 Oct;7(10):973-83 [11279544.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):180-6 [11289755.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:597-607 [11268388.001]
  • [Cites] Cell Mol Life Sci. 1999 Oct 30;56(5-6):481-506 [11212300.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Proc Soc Exp Biol Med. 2000 Nov;225(2):143-50 [11044257.001]
  • [Cites] Int J Immunopharmacol. 2000 Dec;22(12):1067-76 [11137613.001]
  • [Cites] Cancer Lett. 2000 Oct 16;159(1):9-13 [10974400.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] J Neurooncol. 1999;45(3):229-35 [10845393.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):515-8 [10769716.001]
  • [Cites] Int J Immunopharmacol. 2000 Apr;22(4):261-73 [10689100.001]
  • [Cites] J Neuroimmunol. 1999 Dec;100(1-2):216-32 [10695732.001]
  • [Cites] Acta Anaesthesiol Scand. 2000 Jan;44(1):82-7 [10669277.001]
  • [Cites] Drug Metab Lett. 2007 Aug;1(3):199-204 [19356044.001]
  • [Cites] BioDrugs. 1998 Jun;9(6):477-86 [18020580.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):908-13 [17512905.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):301-8 [17433871.001]
  • [Cites] Transplant Proc. 2007 Jan-Feb;39(1):115-9 [17275486.001]
  • [Cites] J Viral Hepat. 2006 Dec;13(12):845-50 [17109685.001]
  • [Cites] J Exp Ther Oncol. 2005;5(1):9-13 [16416596.001]
  • [Cites] Int J Immunopharmacol. 1999 Jan;21(1):15-26 [10411279.001]
  • [Cites] Biotechniques. 1999 Jun;26(6):1073-6, 1078 [10376144.001]
  • [Cites] Hepatology. 1998 Apr;27(4):1128-35 [9537454.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):2155-62 [9529005.001]
  • [Cites] Neuroimmunomodulation. 1997 May-Jun;4(3):163-70 [9500150.001]
  • [Cites] Int J Immunopharmacol. 1997 Jun;19(6):323-32 [9467751.001]
  • [Cites] Anticancer Drugs. 1996 May;7(3):312-20 [8792006.001]
  • [Cites] Arch Androl. 1995 Sep-Oct;35(2):149-54 [8579476.001]
  • [Cites] Arch Androl. 1995 Jul-Aug;35(1):63-9 [8554434.001]
  • [Cites] Immunopharmacology. 1993 Sep-Oct;26(2):171-9 [8282541.001]
  • [Cites] Viral Immunol. 1991 Fall;4(3):195-9 [1810323.001]
  • [Cites] Lymphokine Cytokine Res. 1992 Oct;11(5):277-85 [1467368.001]
  • [Cites] Int J Immunopharmacol. 1992 Jan;14(1):1-9 [1582729.001]
  • [Cites] Immunopharmacol Immunotoxicol. 1990;12(4):595-617 [2092041.001]
  • [Cites] Immunopharmacol Immunotoxicol. 1988;10(4):443-61 [2977606.001]
  • [Cites] Immunopharmacology. 1988 Mar-Apr;15(2):73-84 [2967267.001]
  • [Cites] Immunopharmacology. 1989 May-Jun;17(3):167-73 [2504679.001]
  • [Cites] Curr Treat Options Oncol. 2000 Dec;1(5):459-68 [12057153.001]
  • (PMID = 20111737.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R37 AA011431; United States / NCI NIH HHS / CA / R01 CA123544; United States / NCRR NIH HHS / RR / P20 RR015578; United States / NIAAA NIH HHS / AA / R01 AA012908; United States / NIAAA NIH HHS / AA / R56 AA011431; United States / NIAAA NIH HHS / AA / R01 AA011431; United States / NIAAA NIH HHS / AA / R01 AA002666; United States / NCI NIH HHS / CA / R01 CA035711; United States / NCI NIH HHS / CA / R37 CA035711; United States / NIAAA NIH HHS / AA / R37 AA002666
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2810470
  •  go-up   go-down


22. Karaca M, Andrieu MN, Hicsonmez A, Guney Y, Kurtman C: Cases of glioblastoma multiforme metastasizing to spinal cord. Neurol India; 2006 Dec;54(4):428-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cases of glioblastoma multiforme metastasizing to spinal cord.
  • Cases of glioblastoma multiforme (GBM) metastasizing to the leptomeninx or the intramedullary spine are quite rare and prognoses are relatively poor.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Meningeal Neoplasms / secondary. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114859.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


23. Hau P, Kunz-Schughart LA, Rümmele P, Arslan F, Dörfelt A, Koch H, Lohmeier A, Hirschmann B, Müller A, Bogdahn U, Bosserhoff AK: Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas. J Neurooncol; 2006 Mar;77(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas.
  • BACKGROUND: Tenascin-C is an extracellular matrix protein known to correlate with prognosis in patients with glioblastoma, probably by stimulation of invasion and neoangiogenesis.
  • Transforming Growth Factor-beta1 (TGF-beta1) plays an important role in the biology of high-grade gliomas, partly by regulating invasion of these tumors into parenchyma.
  • This study was designed to evaluate if TGF-beta1 induces the expression and deposition of Tenascin-C in the extracellular matrix of high-grade gliomas which may be pivotal for the invasion of these tumors into healthy parenchyma.
  • METHODS: A series of 20 high-grade gliomas was stained immunohistochemically with Tenascin-C- and TGF-beta1- specific antibodies.
  • CONCLUSION: In our series, Tenascin-C and TGF-beta1 were expressed in the vast majority of high-grade gliomas.
  • Nevertheless, we describe induction of Tenascin-C by TGF-beta1, possibly providing a mechanism for the invasion of high-grade gliomas into healthy parenchyma.
  • [MeSH-major] Brain Neoplasms / metabolism. Extracellular Matrix Proteins / metabolism. Glioma / metabolism. Tenascin / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Child. Disease Progression. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Gliosarcoma / genetics. Gliosarcoma / metabolism. Gliosarcoma / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / analysis. Time Factors. Transforming Growth Factor beta1. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 9;316(3):937-42 [15033492.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] Radiother Oncol. 2004 Sep;72(3):297-303 [15450728.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):235-40 [11118570.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:163-7 [14531574.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):430-46 [15136790.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):1107-10 [11496325.001]
  • [Cites] Oncogene. 2004 Mar 4;23(9):1656-67 [15001984.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Mar;54(2):236-44 [7876891.001]
  • [Cites] Cancer Treat Res. 2004;117:169-90 [15015561.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1029-40 [10515226.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):251-8 [10861501.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2660-8 [11980665.001]
  • [Cites] Microsc Res Tech. 2001 Feb 15;52(4):401-10 [11170299.001]
  • [Cites] Acta Neuropathol. 1989;78(2):189-93 [2750489.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3622-33 [15116096.001]
  • [Cites] Int J Cancer. 1991 Aug 19;49(1):129-39 [1874566.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):199-203 [8054266.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):177-85 [11716069.001]
  • [Cites] Acta Neuropathol. 2002 Jul;104(1):85-91 [12070669.001]
  • [Cites] Biol Chem. 2002 Sep;383(9):1407-13 [12437133.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • (PMID = 16292494.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / TGFB1 protein, human; 0 / Tenascin; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


24. Zhang W, Zhao J, Guo D, Zhong W, Shu J, Luo Y: [Application of susceptibility weighted imaging in revealing intratumoral blood products and grading gliomas]. J Radiol; 2010 Apr;91(4):485-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of our study was to evaluate the application of SWI for revealing inratumoral blood products and diagnosing high-grade gliomas.
  • MATERIALS AND METHODS: Conventional MR sequences and SWI were performed in 32 patients, 10 low-grade gliomas (1 grade I and 9 grade II) and 22 high-grade gliomas (8 grade III and 14 grade IV).
  • Logistic regression and Receiver operating characteristic (ROC) curve analysis were used to evaluate the diagnostic value of SWI for high-grade gliomas.
  • No statistical difference was found in detection rate of blood products between low-grade and high-grade group.
  • According to the result of logistic regression, the frequency of blood products and the diameter of maximum blood products were significant determinants of high-grade gliomas.
  • The result of ROC analysis indicated that with an optimal cut-off point (0.67), the sensitivity, specificity, positive predictive value and negative predictive value for diagnosing high-grade gliomas with blood products detected by SWI were 81.8%, 80.0%, 90.0%, and 66.6%, respectively.
  • With a high-grade gliomas risk estimation model based on two variables, satisfied sensitivity, specificity, PPV and NPV were obtained.
  • [MeSH-major] Blood Proteins / analysis. Brain Neoplasms / diagnosis. Glioma / diagnosis. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / pathology. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Hemorrhage / diagnosis. Hemorrhage / pathology. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514004.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down


25. Kageji T, Nagahiro S, Matsuzaki K, Mizobuchi Y, Toi H, Nakagawa Y, Kumada H: Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma-correlation between radiation dose and radiation injury and clinical outcome. Int J Radiat Oncol Biol Phys; 2006 Aug 1;65(5):1446-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: The first protocol (P1998, n = 8) prescribed a maximal gross tumor volume (GTV) dose of 15 Gy.
  • The mean GTV and CTV dose in long-term survivors with glioblastoma was 26.4 and 16.5 Gy, respectively.
  • In the 11 glioblastoma patients in P2001, the median survival time was 19.5 months and 1- and 2-year survival rate was 60.6% and 37.9%, respectively.
  • For long-term survival in patients with glioblastoma after boron neutron capture therapy, the optimal mean dose of the GTV and CTV was 26 and 16 Gy, respectively.
  • [MeSH-major] Borohydrides / therapeutic use. Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neuroectodermal Tumors, Primitive / radiotherapy. Sulfhydryl Compounds / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Middle Aged. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750328.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Borohydrides; 0 / Sulfhydryl Compounds; 12294-22-3 / mercaptoundecahydrododecaborate
  •  go-up   go-down


26. Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C, Fukushima T: Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol; 2007 Jan;17(1):5-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression.
  • The aim of the present study was to elucidate genetic alterations that are critically involved in astrocytoma progression.
  • We characterized 27 World Health Organization grade II fibrillary astrocytomas which later underwent recurrence or progression, paying specific attention to the CpG island methylation status of critical growth regulatory genes. p14(ARF) and O(6)-methylguanine-DNA methyltransferase (MGMT) hypermethylation represented frequent events (26% and 63%, respectively), which were mutually exclusive except in one case, with alternate or simultaneous methylation of these two genes occurring in 85% of our tumor series.
  • Methylation of the p21(Waf1/Cip1), p27(Kip1) and p73 genes and homozygous deletion of the p16(INK4a), p15(INK4b) and p14(ARF) genes were not detected in any of the primary low-grade tumors.
  • On analysis of their respective recurrent tumors, five of six patients whose primary low-grade tumors carried p14(ARF) methylation exhibited homozygous co-deletions of the p14(ARF), p15(INK4b) and p16(INK4a) genes, which were restricted to glioblastoma as the most malignant end point.
  • Our findings suggest that p14(ARF) hypermethylation and MGMT hypermethylation constitute distinct molecular pathways of astrocytoma progression, which could differ in biological behavior and clinical outcome.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. CpG Islands / physiology. Neoplasm Recurrence, Local / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Tumor Suppressor Protein p14ARF / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Methylation. Middle Aged. Mutation / genetics. Promoter Regions, Genetic / physiology. Survival Analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493032.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


27. Papageorgiou SG, Kolovou D, Bonakis A, Kontaxis T, Moulopoulou A, Kalfakis N: Concommitant appearance of glioblastoma multiforme and neurocysticercosis in a nonendemic country: a case report. Neurologist; 2009 Sep;15(5):293-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concommitant appearance of glioblastoma multiforme and neurocysticercosis in a nonendemic country: a case report.
  • Glioblastoma multiforme, a not infrequent brain neoplasm in young adults, may have a similar clinical and radiologic presentation as NC.
  • Coexistence of NC and brain tumors has been very rarely reported and puts into question a causal relationship between the 2 diseases.
  • Here we report the case of a patient in which glioblastoma multiforme and cysticercosis appeared concomitantly, making their clinical distinction very difficult.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / pathology. Glioblastoma / complications. Glioblastoma / pathology. Neurocysticercosis / complications. Neurocysticercosis / pathology
  • [MeSH-minor] Adult. Brain / pathology. Fatal Outcome. Female. Greece. Humans

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19741440.001).
  • [ISSN] 2331-2637
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Maesawa S, Fujii M, Nakahara N, Watanabe T, Wakabayashi T, Yoshida J: Intraoperative tractography and motor evoked potential (MEP) monitoring in surgery for gliomas around the corticospinal tract. World Neurosurg; 2010 Jul;74(1):153-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumor removal was performed in 28 patients with gliomas in and around the corticospinal tract (CST), in an operation theater equipped with an integrated high-field intraoperative magnetic resonance imaging and a neuronavigation system.
  • The results of the linear regression between distance and stimulation intensity were informative for guiding approaches to tumor remnants without impinging on the CST.
  • [MeSH-major] Brain Neoplasms / surgery. Cerebral Cortex / surgery. Diffusion Magnetic Resonance Imaging / methods. Evoked Potentials, Motor / physiology. Glioblastoma / surgery. Glioma / surgery. Image Processing, Computer-Assisted / methods. Monitoring, Intraoperative / methods. Neuronavigation. Pyramidal Tracts / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebral Infarction / etiology. Cerebral Infarction / physiopathology. Craniotomy. Evoked Potentials, Somatosensory / physiology. Female. Humans. Male. Microsurgery. Middle Aged. Paresis / etiology. Paresis / physiopathology. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] World Neurosurg. 2010 Jul;74(1):105-6 [21299993.001]
  • [CommentIn] World Neurosurg. 2010 Jul;74(1):107-8 [21299994.001]
  • (PMID = 21300007.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Moise D, Madhusoodanan S: Psychiatric symptoms associated with brain tumors: a clinical enigma. CNS Spectr; 2006 Jan;11(1):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychiatric symptoms associated with brain tumors: a clinical enigma.
  • Patients in psychiatric settings may present with medical conditions, such as brain tumors, which may or may not be associated with neurological symptoms.
  • Brain tumors may be detected in patients at their first presentation to mental health services or sometimes in patients with well-established psychiatric diagnoses.
  • Brain imaging showed the presence of a left thalamic tumor, later confirmed as glioblastoma multiforme.
  • With this we show that in some cases, brain tumors can be neurologically silent and only present atypical psychiatric symptoms.
  • [MeSH-major] Brain Neoplasms / complications. Depressive Disorder, Major / etiology. Stress Disorders, Post-Traumatic / etiology
  • [MeSH-minor] Adult. Female. Functional Laterality. Humans. Severity of Illness Index. Thalamus / surgery


30. Song SW, Fuller GN, Zheng H, Zhang W: Inactivation of the invasion inhibitory gene IIp45 by alternative splicing in gliomas. Cancer Res; 2005 May 1;65(9):3562-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The invasion inhibitory protein 45 (IIp45) we recently identified was underexpressed in glioblastoma multiforme, the most malignant form of glioma.
  • The IIp45 gene is located at chromosome 1p36 where frequent deletions have been reported in various types of tumors, including gliomas, raising the possibility that IIp45 may be a classic tumor suppressor gene that can be inactivated by frequent point mutations.
  • To test this hypothesis, we sequenced the IIp45 gene in 59 diffuse glioma samples of different grades and histologic subtypes and identified a possible point mutation or a rare polymorphism in only one sample (1.7%), suggesting that IIp45 is not a classic tumor suppressor gene such as p53.
  • Instead, reverse transcription-PCR and subsequent sequencing results revealed a tumor-specific IIp45 spliced isoform (IIp45S) in 20 of 59 (34%) gliomas examined, particularly in glioblastoma multiformes, including native tissue samples (15 of 25; 60%) and cell lines (5 of 5; 100%).
  • The alternative splicing event is independent of 1p36 deletion, which is not common in glioblastoma multiforme.
  • The IIp45S transcript was not detected in any of 18 normal organs, including fetal and adult brain.
  • Thus, the IIp45 gene is inactivated by a tumor-specific alternative splicing that generates an aberrant and unstable IIp45 isoform in infiltrative gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Carrier Proteins / antagonists & inhibitors. Carrier Proteins / genetics. Glioma / genetics
  • [MeSH-minor] Alternative Splicing. Cell Line, Tumor. DNA Mutational Analysis. DNA, Neoplasm / genetics. Exons. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Proteasome Endopeptidase Complex / metabolism. Protein Isoforms. Ubiquitin / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867349.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / IIp45 protein, human; 0 / Protein Isoforms; 0 / Ubiquitin; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


31. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S: Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol; 2010 Sep;99(2):261-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
  • Despite resection, radiochemotherapy, and maintenance temozolomide chemotherapy (TMZm), the prognosis of patients with glioblastoma multiforme (GBM) remains poor.
  • We integrated immunotherapy in the primary standard treatment for eight pilot adult patients (median age 50 years) with GBM, to assess clinical and immunological feasibility and toxicity in preparation of a phase I/II protocol HGG-2006.
  • In five patients, a more than twofold increase in tumor antigen-reacting IFN-gamma-producing T cells on Elispot was seen at the fourth vaccination compared with before vaccination.
  • We conclude that tumor vaccination, fully integrated within the standard primary postoperative treatment for patients with newly diagnosed GBM, is feasible and well tolerated.
  • [MeSH-major] Brain Neoplasms / therapy. Cancer Vaccines / administration & dosage. Dendritic Cells / immunology. Glioblastoma / therapy. Immunotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Feasibility Studies. Female. Humans. Male. Middle Aged. Pilot Projects. Quality of Life. Radiotherapy Dosage. Survival Rate. Transplantation, Autologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2006 Mar;55(3):254-67 [16133115.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8065-8 [16166276.001]
  • [Cites] Neurosurg Focus. 2000 Dec 15;9(6):e8 [16817691.001]
  • [Cites] Melanoma Res. 2006 Aug;16(4):357-63 [16845332.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(10):935-42 [15806121.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6451-8 [11522640.001]
  • [Cites] Int Immunol. 2004 Dec;16(12):1769-80 [15520045.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):196-201 [9754652.001]
  • [Cites] Neurosurg Focus. 2003 Feb 15;14(2):e1 [15727422.001]
  • [Cites] J Exp Med. 1986 Nov 1;164(5):1652-66 [2945892.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):842-7 [11221866.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] In Vivo. 1992 Sep-Oct;6(5):531-4 [1457747.001]
  • [Cites] Klin Padiatr. 1996 Sep-Oct;208(5):294-8 [8992097.001]
  • [Cites] J Neurosurg. 2005 Jul;103(1):156-64 [16121986.001]
  • [Cites] Glia. 1995 Nov;15(3):211-21 [8586458.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1033-6 [12532024.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] J Clin Epidemiol. 1997 Apr;50(4):441-50 [9179103.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1656-62 [15477864.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):337-44 [11676393.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3098-104 [18483377.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5226-34 [15897911.001]
  • [Cites] Neuro Oncol. 2009 Oct;11(5):529-42 [19336528.001]
  • [Cites] Cell Death Differ. 2006 Jul;13(7):1238-41 [16456578.001]
  • [Cites] Cancer Immunol Immunother. 1984;16(3):175-81 [6231095.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Immunol Today. 1991 Oct;12(10):370-4 [1958290.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):275-88 [8864284.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3294-302 [16540683.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000 [17143233.001]
  • [Cites] J Immunol. 2003 Nov 1;171(9):4927-33 [14568975.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5316-26 [15328167.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):123-31 [17522861.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4160-7 [15930352.001]
  • [Cites] J Neurooncol. 2009 Jan;91(2):127-39 [18787761.001]
  • [Cites] J Transl Med. 2007 Dec 19;5:67 [18093335.001]
  • [Cites] J Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7 [15287461.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):334-45 [8941873.001]
  • [Cites] Mol Cancer. 2006 Dec 02;5:67 [17140455.001]
  • [Cites] Cancer Immunol Immunother. 2005 Apr;54(4):372-82 [15692847.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] J Immunother. 2004 Nov-Dec;27(6):452-9 [15534489.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] Brain Pathol. 2009 Oct;19(4):694-712 [19744041.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Cancer Immunol Immunother. 2001 Aug;50(6):321-7 [11570586.001]
  • [Cites] Cancer Immunol Immunother. 1999 Jul;48(4):214-7 [10431692.001]
  • [Cites] Nat Rev Immunol. 2002 Aug;2(8):547-56 [12154374.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1172-9 [14520441.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):131-40 [17361330.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2665-76 [10953341.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4490-6 [12907622.001]
  • [Cites] J Clin Neurosci. 2008 Feb;15(2):114-21 [18083572.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5955-64 [18632651.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 20146084.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


32. Aoki T, Takahashi JA, Ueba T, Oya N, Hiraoka M, Matsui K, Fukui T, Nakashima Y, Ishikawa M, Hashimoto N: Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg; 2006 Sep;105(3):385-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group.
  • During the course of radiotherapy, the percentages of patients who experienced Grade 3 toxicity were 14% with neurocytopenia and 7% with thrombocytopenia.
  • Seven percent of all adjuvant chemotherapy cycles following radiotherapy were associated with Grade 3 toxicity, as manifested in neurocytopenia or thrombocytopenia.
  • No instance of Grade 4 toxicity was observed.
  • CONCLUSIONS: The combination of ACNU-carboplatin-vincristine-IFNbeta chemotherapy and radiotherapy is safe and well tolerated, and may prolong survival in patients with glioblastoma multiforme.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Drug Tolerance. Female. Humans. Interferon-beta / administration & dosage. Male. Middle Aged. Nimustine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961130.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine; 77238-31-4 / Interferon-beta; BG3F62OND5 / Carboplatin
  •  go-up   go-down


33. Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T, Jain V: Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol; 2005 Aug;181(8):507-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
  • Since higher 2-DG doses are expected to improve the therapeutic gain, present studies were undertaken to examine the tolerance and safety of escalating 2-DG dose during combined treatment (2-DG + radiotherapy) in glioblastoma multiforme patients.
  • PATIENTS AND METHODS: Untreated patients with histologically proven glioblastoma multiforme (WHO criteria) were included in the study.
  • Seven weekly fractions of (60)Co gamma-rays (5 Gy/fraction) were delivered to the tumor volume (presurgical CT/MRI evaluation) plus 3 cm margin.
  • No significant damage to the normal brain tissue was observed during follow-up in seven out of ten patients who received complete treatment and survived between 11 and 46 months after treatment.
  • CONCLUSION: Oral administration of 2-DG combined with large fractions of radiation (5 Gy/fraction/week) is safe and could be tolerated in glioblastoma patients without any acute toxicity and late radiation damage to the normal brain.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Deoxyglucose / administration & dosage. Glioblastoma / radiotherapy. Radiopharmaceuticals / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Cobalt Radioisotopes / therapeutic use. Dose Fractionation. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Radiotherapy Dosage. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044218.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; 0 / Radiopharmaceuticals; 9G2MP84A8W / Deoxyglucose
  •  go-up   go-down


34. Sheehan KM, Kay EW, Burke M, Heffernan J, Brett FM, Farrell MA: Unrepresentative astrocytoma biopsy sampling is partly overcome by assessment of the MIB-1-labelled growth fraction. J Clin Pathol; 2007 Aug;60(8):945-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrepresentative astrocytoma biopsy sampling is partly overcome by assessment of the MIB-1-labelled growth fraction.
  • [MeSH-major] Astrocytoma / immunology. Central Nervous System Neoplasms / immunology. Ki-67 Antigen / analysis
  • [MeSH-minor] Adult. Biopsy / methods. Glioblastoma / immunology. Humans. Immunohistochemistry / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 1991;5(3):289-98 [1892572.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Am J Surg Pathol. 1986 Sep;10(9):611-7 [2428262.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):653-62 [12152780.001]
  • [Cites] Histopathology. 2003 Jan;42(1):70-6 [12493028.001]
  • [Cites] J Neurooncol. 1999;44(3):255-66 [10720205.001]
  • (PMID = 17412876.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC1994483
  •  go-up   go-down


35. Miyatake S, Kawabata S, Yokoyama K, Kuroiwa T, Michiue H, Sakurai Y, Kumada H, Suzuki M, Maruhashi A, Kirihata M, Onoc K: Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S22-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have applied boron neutron capture therapy (BNCT) to malignant brain tumors.
  • Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n=22; 95% CI, 7.3-12.8 months) and 9.6 months (n=19; 95% CI, 6.9-11.4 months), respectively.
  • [MeSH-major] Boron Neutron Capture Therapy. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Glioblastoma / classification. Glioblastoma / mortality. Glioblastoma / pathology. Glioblastoma / radiotherapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394240.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Galldiks N, Ullrich R, Schroeter M, Fink GR, Kracht LW: Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. J Neurooncol; 2009 Jul;93(3):425-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen.
  • PROCEDURES: Therapeutic effects were monitored in a 26-year-old male patient with a glioblastoma multiforme by multimodal imaging using sequential L: -[methyl-(11)C]-methionine positron emission tomography (MET-PET) and MRI.
  • The normalized MET uptake and volume of the metabolically active tumor were assessed sequentially.
  • RESULTS: The individual patient-tailored, experimental glioma therapy caused a continuous decline of metabolically active tumor volume, associated with clinical remission over a period of more than two years.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Brain Neoplasms / therapy. Glioblastoma / radionuclide imaging. Glioblastoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Combined Modality Therapy. Cranial Irradiation. Humans. Hydroxyurea / administration & dosage. Imatinib Mesylate. Male. Neurosurgical Procedures. Piperazines / administration & dosage. Positron-Emission Tomography. Pyrimidines / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5143-50 [11016641.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):645-52 [11870241.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):481-7 [12181402.001]
  • [Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]
  • [Cites] Int J Appl Radiat Isot. 1979 Jul;30(7):393-9 [478664.001]
  • [Cites] J Neurooncol. 1986;3(4):397-404 [3485705.001]
  • [Cites] Acta Radiol. 1990 Sep;31(5):417-29 [2261284.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • [Cites] Eur J Nucl Med. 1996 May;23(5):583-6 [8698067.001]
  • [Cites] J Nucl Med. 1997 Feb;38(2):280-7 [9025756.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Jun;38(6):342-7; discussion 347-8 [9689817.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):129-35 [9711745.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]
  • [Cites] Brain. 2005 Mar;128(Pt 3):678-87 [15689365.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] Med Hypotheses. 2005;65(6):1205-6 [16109460.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 May;33(5):516-24 [16450140.001]
  • [Cites] J Neurol Sci. 2000 Feb 1;173(1):25-31 [10675576.001]
  • (PMID = 19183853.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; X6Q56QN5QC / Hydroxyurea
  • [Other-IDs] NLM/ PMC2758365
  •  go-up   go-down


37. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, Zanusso M, Palù G: Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther; 2005 Oct;12(10):835-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results.
  • Following our pilot clinical study of combined IL-2/HSV-TK gene therapy for recurrent glioblastoma multiforme (GBM), we extended the protocol to a larger population of patients and evaluated safety, feasibility, and biological activity of treatment.
  • Transduction of tumor cells was demonstrated in tumor biopsies.
  • At magnetic resonance imaging evaluation, two patients had a partial response (including a patient showing disappearance of a distant noninjected tumor mass), four had a minor response, four had stable disease, and two had progressive disease.
  • In conclusion, the results of our clinical protocol of gene therapy for recurrent GBM, based on combined delivery of a suicide and a cytokine gene, demonstrate that intratumor injection of RVPCs was safe, provided effective transduction of the therapeutic genes to target tumor cells, and activated a systemic cytokine cascade, with tumor responses in 50% of cases.
  • [MeSH-major] Brain Neoplasms / therapy. Genes, Transgenic, Suicide / genetics. Genetic Therapy / methods. Glioblastoma / therapy. Interleukin-2 / therapeutic use. Simplexvirus. Thymidine Kinase / therapeutic use
  • [MeSH-minor] Adult. Aged. Cytokines / blood. Cytokines / metabolism. DNA Primers. Female. Genetic Vectors / genetics. Genetic Vectors / therapeutic use. Humans. Male. Middle Aged. Moloney murine leukemia virus. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891772.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA Primers; 0 / Interleukin-2; EC 2.7.1.21 / Thymidine Kinase
  •  go-up   go-down


38. Fox SW, Lyon D, Farace E: Symptom clusters in patients with high-grade glioma. J Nurs Scholarsh; 2007;39(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptom clusters in patients with high-grade glioma.
  • PURPOSE: To describe the co-occurring symptoms (depression, fatigue, pain, sleep disturbance, and cognitive impairment), quality of life (QoL), and functional status in patients with high-grade glioma.
  • DESIGN: Correlational, descriptive study of 73 participants with high-grade glioma in the U.S.
  • Participants were recruited from the online message board of The Healing Exchange BRAIN TRUST, a nonprofit organization dedicated to improving quality of life for people with brain tumors.


39. Kocher M, Kunze S, Eich HT, Semrau R, Müller RP: Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol; 2005 Mar;181(3):157-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From 11/1999 to 03/2003, n = 81 patients aged 15-72 years (median 52 years, Karnofsky score 80-100% in 83%) suffering from primary glioblastoma (n = 47), anaplastic astrocytoma (n = 6), anaplastic oligodendroglioma (n = 16), and recurrent glioma (n = 12) were treated.
  • Grade 1 nausea/vomiting was seen in 28%, grade 2 in 11%, grade 3 in 1%.
  • Hematologic toxicities were observed as follows: leukopenia grade 3/4 1%, lymphopenia grade 3/4 46%, thrombopenia grade 3/4 1%.
  • Median survival was 15 months for glioblastoma.
  • The combined schedule is effective in oligodendroglioma patients and may prolong survival in glioblastoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / surgery. Dacarbazine / analogs & derivatives. Glioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756519.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


40. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ: Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer; 2008 Jul 15;113(2):405-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ) is now the standard of care for patients with newly diagnosed glioblastoma.
  • METHODS: The pre-RT and post-RT brain scans from patients treated with RT/TMZ for a malignant glioma were reviewed.
  • Six of 18 patients with pseudo-progression and 12 of the 18 patients with real tumor progression developed new clinical signs and symptoms during RT or in the first 4 weeks thereafter.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Combined Modality Therapy. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18484594.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


41. Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S: High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Eur J Endocrinol; 2009 Oct;161(4):553-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After all these treatments failed, the patient had monthly temozolomide administrations, resulting in gradual clinical improvement and biochemical data that were consistent with tumor shrinkage.
  • In glioblastoma, low O(6)-methylguanine DNA methyltransferase (MGMT) expression is associated with epigenetic gene silencing and predicts a better response to temozolomide.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19589911.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9002-60-2 / Adrenocorticotropic Hormone; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


42. Combs SE, Gutwein S, Schulz-Ertner D, van Kampen M, Thilmann C, Edler L, Wannenmacher MM, Debus J: Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol; 2005 Jun;181(6):372-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
  • BACKGROUND AND PURPOSE: The role of radiochemotherapy in the treatment of primary glioblastoma multiforme is still discussed controversially.
  • PATIENTS AND METHODS: 53 Patients with histologically confirmed WHO grade IV malignant glioma were enrolled into the study.
  • RESULTS: Prior to radiochemotherapy, complete resection (n = 14), subtotal resection (n = 22) or a biopsy (n = 17) of the tumor was performed.
  • Acute toxicity > grade 2 was observed in one patient who developed grade 4 hemotoxicity.
  • Further evaluation is warranted as to which dose of temozolomide is optimal with regard to tumor response and toxicity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / toxicity. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Blood Cell Count. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925979.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


43. Malmer BS, Feychting M, Lönn S, Lindström S, Grönberg H, Ahlbom A, Schwartzbaum J, Auvinen A, Collatz-Christensen H, Johansen C, Kiuru A, Mudie N, Salminen T, Schoemaker MJ, Swerdlow AJ, Henriksson R: Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol; 2007 May;82(3):229-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: P53 and ATM are central checkpoint genes involved in the repair of DNA damage after ionising irradiation, which has been associated with risk of brain tumours.
  • MATERIAL AND METHODS: Six hundred and eighty glioma cases (298 glioblastoma (GBM)), 503 meningioma cases, and 1555 controls recruited in the Nordic-UK Interphone study, were analysed in association with three polymorphisms in p53 (rs2287499, rs1042533, rs1625895) and five polymorphisms in ATM ( rs228599, rs3092992, rs664143, rs170548, rs3092993).
  • RESULTS: The global statistical test of glioblastoma and p53 haplotypes was p = 0.02.
  • The haplotype analysis on glioblastoma revealed the 1-2-2 haplotype (promotor-codon72-intron 6) had a frequency of 6.1% in cases compared with 9.8% in controls (p = 0.003).
  • CONCLUSIONS: This study found both positive and negative associations of haplotypes in p53 for glioblastoma and ATM for meningioma.
  • This study provides new data that could add to our understanding of brain tumour susceptibility.
  • [MeSH-major] Brain Neoplasms / genetics. Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Glioma / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Ataxia Telangiectasia Mutated Proteins. Case-Control Studies. Female. Genetic Predisposition to Disease. Haplotypes. Humans. Male. Middle Aged. Polymorphism, Single Nucleotide. Risk Factors

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 May 21;393(6682):229-34 [9607760.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):260-5 [15942625.001]
  • [Cites] Hum Genet. 2005 Dec;118(3-4):339-47 [16189707.001]
  • [Cites] J Pathol. 2003 Nov;201(3):377-88 [14595749.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5710-3 [11479203.001]
  • [Cites] Int J Radiat Biol. 1994 Dec;66(6 Suppl):S57-62 [7836853.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):681-90 [11983757.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):78-81 [10585587.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8717-25 [14695186.001]
  • [Cites] Biol Res. 2003;36(2):279-83 [14513722.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):868-72 [16041375.001]
  • [Cites] Hum Hered. 1995 May-Jun;45(3):144-9 [7615299.001]
  • [Cites] Nat Rev Genet. 2005 Feb;6(2):109-18 [15716907.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Feb;32(2):229-46 [15657757.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):495-507 [16212814.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):307-15 [15549092.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):813-22 [15928302.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):461-7 [15006924.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5560-3 [15313891.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2220-3 [16172235.001]
  • [Cites] Hum Hered. 1996 Jan-Feb;46(1):41-8 [8825462.001]
  • [Cites] Breast Cancer Res. 2004;6(4):R416-22 [15217510.001]
  • [Cites] Genome Res. 2002 Dec;12(12):1846-53 [12466288.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):14-22 [12540498.001]
  • [Cites] Physiol Res. 2002;51(1):59-64 [12071291.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Int J Gynaecol Obstet. 2004 Jun;85(3):301-8 [15145278.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14 (4):969-76 [15824172.001]
  • (PMID = 17151932.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


44. Chamberlain MC, Johnston SK: Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol; 2010 Jan;96(2):259-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
  • A retrospective evaluation of single agent bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (16 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (7; 1 grade 3), deep vein thrombosis (4; 1 grade 3) and wound dehiscence (2; 1 grade 3).
  • Time to tumor progression ranged from 0.5 to 15 months (median: 1.0 months).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Blood Cell Count. Creatinine / urine. Disease-Free Survival. Female. Humans. Injections, Intravenous / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1981 Nov;55(5):749-56 [7310496.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] Nat Clin Pract Neurol. 2006 Jun;2(6):288-9 [16932567.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]
  • [Cites] Neuro Oncol. 2009 Oct;11(5):550-5 [19332770.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Nature. 2005 Sep 22;437(7058):497-504 [16177780.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):253-8 [15279718.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] Cell. 2007 Nov 2;131(3):443-5 [17981110.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]
  • [Cites] Cancer Res. 1991 Oct 15;51(20):5760-5 [1717153.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Cancer Treat Res. 2004;117:169-90 [15015561.001]
  • [Cites] Expert Opin Biol Ther. 2008 Apr;8(4):541-53 [18352856.001]
  • [Cites] Stat Med. 1991 May;10(5):749-55 [2068428.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] J Clin Oncol. 1999 May;17 (5):1516-25 [10334539.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3560-4 [17440065.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Surg Neurol. 1993 Jun;39(6):538-43 [8390727.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10 ):733-6 [17882276.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2352-8 [12712456.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2066-7 [18463385.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3127-39 [17098419.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] J Neurosurg. 1990 Apr;72 (4):583-8 [2319317.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] Cancer. 2008 May 15;112(10 ):2267-73 [18327820.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6 [1651302.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Oct;18(5):1161-81, x [15474340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):593-7 [1429080.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Oncology. 2005;69 Suppl 3:11-6 [16301831.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1129-36 [18337603.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4033-42 [17827451.001]
  • [Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):475-85 [17522716.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1485-91 [12697871.001]
  • [Cites] J Neurooncol. 2001 Nov;55(2):91-100 [11817706.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • (PMID = 19593660.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; AYI8EX34EU / Creatinine
  •  go-up   go-down


45. Aoki T, Mizutani T, Nojima K, Takagi T, Okumura R, Yuba Y, Ueba T, Takahashi JA, Miyatake S, Nozaki K, Taki W, Matsutani M: Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg; 2010 Jan;112(1):50-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
  • OBJECT: The prognosis of recurrent glioblastoma multiforme (GBM) remains unsatisfactory.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Brain Neoplasms / drug therapy. Carboplatin / therapeutic use. Etoposide / therapeutic use. Glioblastoma / drug therapy. Ifosfamide / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Quality of Life. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538050.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


46. Nishi N, Kawai S, Yonezawa T, Fujimoto K, Masui K: Early appearance of high grade glioma on magnetic resonance imaging. Neurol Med Chir (Tokyo); 2009 Jan;49(1):8-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early appearance of high grade glioma on magnetic resonance imaging.
  • The early appearance of high grade glioma on magnetic resonance (MR) imaging was retrospectively reviewed in the clinical records and MR images of 52 patients with intracerebral glioma treated in Osaka General Medical Center between 1997 and 2006.
  • Six of the seven patients developed tumor progression within only 5 months.
  • All patients underwent surgical tumor resection and the histological diagnoses were all high grade gliomas, glioblastomas in five, gliosarcoma in one, and anaplastic astrocytoma in one.
  • Surveillance MR imaging should be performed at short intervals in adult patients presenting with seizures but with no or minimal abnormalities on initial MR imaging to identify progression of high grade glioma at the earliest opportunity.
  • [MeSH-major] Glioblastoma / diagnosis. Magnetic Resonance Imaging. Supratentorial Neoplasms / diagnosis. Temporal Lobe / pathology
  • [MeSH-minor] Aged. Astrocytoma / diagnosis. Astrocytoma / pathology. Disease Progression. Dizziness / etiology. Early Diagnosis. Fatal Outcome. Female. Gliosarcoma / diagnosis. Gliosarcoma / pathology. Humans. Male. Middle Aged. Seizures / etiology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168996.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Schramm P, Xyda A, Klotz E, Tronnier V, Knauth M, Hartmann M: Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas. Eur Radiol; 2010 Oct;20(10):2482-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas.
  • INTRODUCTION: Perfusion computed tomography (PCT) allows to quantitatively assess haemodynamic characteristics of brain tissue.
  • We investigated if different brain tumor types can be distinguished from each other using Patlak analysis of PCT data.
  • METHODS: PCT data from 43 patients with brain tumours were analysed with a commercial implementation of the Patlak method.
  • Four patients had low-grade glioma (WHO II), 31 patients had glioblastoma (WHO IV) and eight patients had intracerebral lymphoma.
  • RESULTS: In comparison with normal parenchyma, low-grade gliomas showed no significant difference of perfusion parameters (p > 0.05) , whereas high-grade gliomas demonstrated significantly higher values (p < 0.0001 for K (Trans), p < 0.0001 for CBV and p = 0.0002 for CBF).
  • High-grade gliomas show significant higher CBV values than lymphomas (p = 0.0078).
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / pathology. Glioma / diagnosis. Glioma / pathology. Lymphoma / diagnosis. Lymphoma / pathology. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Biopsy. Brain / pathology. Cerebrovascular Circulation. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Perfusion

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):891-9 [10815665.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Stroke. 2001 Feb;32(2):431-7 [11157178.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):193-200 [11465400.001]
  • [Cites] Eur Radiol. 2002 Feb;12(2):329-40 [11870430.001]
  • [Cites] J Magn Reson Imaging. 2002 Mar;15(3):233-40 [11891967.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):746-55 [15140713.001]
  • [Cites] Acad Radiol. 2004 May;11(5):573-82 [15147622.001]
  • [Cites] Stroke. 2004 Jul;35(7):1652-8 [15155964.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Mar;21(3):462-70 [10730636.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Mayo Clin Proc. 1987 Jun;62(6):450-9 [3553757.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jul-Aug;13(4):1207-13 [1636538.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;119(1):7-27 [1400570.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4564-8 [8062241.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):9-19 [7541613.001]
  • [Cites] Radiology. 1996 Mar;198(3):813-8 [8628876.001]
  • [Cites] J Neurooncol. 1997 May;32(3):253-65 [9049887.001]
  • [Cites] AJR Am J Roentgenol. 1998 Oct;171(4):941-9 [9762973.001]
  • [Cites] Eur J Radiol. 1999 Jun;30(3):170-84 [10452715.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):288-96 [16795091.001]
  • [Cites] Neuroradiology. 2006 Oct;48(10):773-81 [16937146.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2729-35 [17363594.001]
  • [Cites] Neuroradiology. 2007 Jul;49 Suppl 1:S35-45 [17665157.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):694-700 [18202239.001]
  • (PMID = 20495977.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2940017
  •  go-up   go-down


48. Sun J, Wang Z, Li Z, Liu B: Microsurgical treatment and functional outcomes of multi-segment intramedullary spinal cord tumors. J Clin Neurosci; 2009 May;16(5):666-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty-six patients with MSICTs underwent microsurgery for tumor removal using a posterior approach.
  • The tumor was exposed through a dorsal myelotomy.
  • Pre-operative and post-operative nervous function was scored using the Improved Japanese Orthopaedic Association (IJOA) grading system.
  • Correlation analyses were performed between functional outcome (IJOA score) and histological features, age, tumor location, and the longitudinal extent of spinal cord involvement.
  • Ependymoma was the most frequent MSICT type, seen in 22 of 56 patients (39%), followed by low grade astrocytoma (17 patients, 30%) and glioblastoma multiforme (3 patients, 5%).
  • Gross total tumor removal was achieved in 33 cases (58%), subtotal resection in 4 (7%), and partial resection in 16 (28%).
  • The histological classification of the tumor was the most important factor influencing the extent of surgical removal (chi2=22.17, p=0.00).
  • Thus, MSICTs were most commonly seen in the medullo cervical and cervicothoracic regions, with ependymoma and low grade astrocytoma the most common tumour types.
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurologic Examination / methods. Outcome Assessment (Health Care). Prospective Studies. Spinal Cord / pathology. Spinal Cord / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303302.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


49. Luz-Madrigal A, Clapp C, Aranda J, Vaca L: In vivo transcriptional targeting into the retinal vasculature using recombinant baculovirus carrying the human flt-1 promoter. Virol J; 2007;4:88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcriptional gene targeting was analyzed in vitro in different mammalian cell lines and in vivo in adult rat retinal vasculature.
  • Interestingly, BacFLT-GFP directed high levels of expression in rat glioma C6 and in human glioblastoma CH235 cells (34.78% and 47.86% relative to BacCMV-GFP, respectively).
  • Thus, in this study histone deacetylation appears to be a central mechanism for the silencing of baculovirus, independently of the promoter utilized.
  • In vivo transcriptional targeting was demonstrated in adult rat retinal vasculature by intravitreal delivery of BacFLT-GFP and immunohistochemical staining with von Willebrand factor (vWF).
  • [MeSH-minor] Animals. Cell Line, Tumor. Genetic Vectors. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Humans. Rats. Recombination, Genetic. Transduction, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 1999;886:23-36 [10667200.001]
  • [Cites] Mol Ther. 2006 Apr;13(4):738-46 [16387551.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14638-43 [11114190.001]
  • [Cites] Diabetes. 2000 Dec;49(12):1986-91 [11117998.001]
  • [Cites] Trends Endocrinol Metab. 2000 May-Jun;11(4):142-8 [10754536.001]
  • [Cites] Hypertension. 2001 Jul;38(1):65-70 [11463761.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Oct 31;52(1):93-102 [11672878.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Dec;42(13):3294-300 [11726636.001]
  • [Cites] Eur J Cell Biol. 2002 Jan;81(1):1-8 [11893074.001]
  • [Cites] Curr Gene Ther. 2002 May;2(2):161-71 [12109213.001]
  • [Cites] Nat Rev Drug Discov. 2002 Apr;1(4):287-99 [12120280.001]
  • [Cites] Nat Rev Genet. 2003 May;4(5):346-58 [12728277.001]
  • [Cites] J Clin Invest. 2003 Jul;112(1):50-7 [12840058.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] J Nutr. 2003 Jul;133(7 Suppl):2485S-2493S [12840228.001]
  • [Cites] Curr Pharm Des. 2004;10(4):407-23 [14965202.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):129-38 [15015778.001]
  • [Cites] Expert Opin Biol Ther. 2004 May;4(5):683-96 [15155160.001]
  • [Cites] Protein Expr Purif. 2004 Nov;38(1):17-23 [15477077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11797-801 [7527544.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10099-103 [7479733.001]
  • [Cites] J Biol Chem. 1995 Nov 17;270(46):27948-53 [7499271.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2348-52 [8637876.001]
  • [Cites] Gene Ther. 1996 Jan;3(1):49-58 [8929911.001]
  • [Cites] Gene Ther. 1996 Dec;3(12):1094-103 [8986436.001]
  • [Cites] Hum Gene Ther. 1997 Mar 1;8(4):403-10 [9054515.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1006-14 [9276717.001]
  • [Cites] Gene Ther. 1998 Apr;5(4):531-6 [9614578.001]
  • [Cites] Hum Gene Ther. 1998 Sep 1;9(13):1919-28 [9741430.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Aug;40(9):2115-21 [10440268.001]
  • [Cites] Mol Med Today. 1999 Oct;5(10):448-53 [10498913.001]
  • [Cites] Exp Physiol. 2005 Jan;90(1):39-44 [15542616.001]
  • [Cites] Exp Physiol. 2005 Jan;90(1):27-31 [15542621.001]
  • [Cites] Nat Biotechnol. 2005 May;23(5):567-75 [15877075.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):3799-807 [16309166.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] Thromb Haemost. 2006 Jan;95(1):49-55 [16543961.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3027-33 [16373660.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5798-806 [16740719.001]
  • [Cites] Gene Ther. 2000 Sep;7(17):1499-504 [11001370.001]
  • (PMID = 17877803.001).
  • [ISSN] 1743-422X
  • [Journal-full-title] Virology journal
  • [ISO-abbreviation] Virol. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  • [Other-IDs] NLM/ PMC2034561
  •  go-up   go-down


50. Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD: Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol; 2010 Jun;12(6):608-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
  • We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
  • At 500 mg, 2 of 6 patients experienced a DLT (1 Grade 4 and 1 Grade 3 thrombocytopenia).
  • The patient with Grade 3 DLT recovered to Grade <1 within 28 days and adjuvant temozolomide and enzastaurin was reinitiated with dose reductions.
  • The other patient recovered to Grade <1 toxicity after 28 days and did not restart treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Indoles / administration & dosage. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 1999;17(3):227-40 [10665476.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1275-9 [19188675.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Feb;53(2):133-40 [14593497.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):816-26 [9669344.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4413-8 [10485491.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47720-5 [15364915.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9062-9 [15489897.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7462-9 [16103100.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4092-9 [16943527.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):47-52 [17108062.001]
  • [Cites] Ann Neurol. 2007 Feb;61(2):153-61 [17212356.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4474-81 [17671132.001]
  • [Cites] J Clin Pharmacol. 2007 Sep;47(9):1138-51 [17766700.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] J Neurooncol. 2000 Apr;47(2):109-15 [10982151.001]
  • (PMID = 20156802.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; UC96G28EQF / enzastaurin
  • [Other-IDs] NLM/ PMC2940647
  •  go-up   go-down


51. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME: Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol; 2008 Jun 20;26(18):3015-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
  • PURPOSE: Glioblastomas are notorious for resistance to therapy, which has been attributed to DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more recently, to the particular biologic behavior of tumor stem-like cells.
  • Better outcome was associated with gene clusters characterizing features of tumor-host interaction including tumor vascularization and cell adhesion, and innate immune response.
  • CONCLUSION: This study provides first clinical evidence for the implication of a "glioma stem cell" or "self-renewal" phenotype in treatment resistance of glioblastoma.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Glioblastoma / pathology. Glioblastoma / therapy. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Resistance, Neoplasm. Gene Expression Profiling. Genes, Homeobox. Humans. Middle Aged. Multigene Family. Radiation Tolerance

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565887.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


52. Evers P, Lee PP, DeMarco J, Agazaryan N, Sayre JW, Selch M, Pajonk F: Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer; 2010 Jul 21;10:384
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma.
  • BACKGROUND: Glioblastoma is the most common brain tumor in adults.
  • The mechanisms leading to glioblastoma are not well understood but animal studies support that inactivation of tumor suppressor genes in neural stem cells (NSC) is required and sufficient to induce glial cancers.
  • This suggests that the NSC niches in the brain may harbor cancer stem cells (CSCs), Thus providing novel therapy targets.
  • METHODS: 55 adult patients with Grade 3 or Grade 4 glial cancer treated with radiotherapy at UCLA between February of 2003 and May of 2009 were included in this retrospective study.
  • CONCLUSIONS: Our study leads us to hypothesize that in glioma targeted radiotherapy of the stem cell niches in the adult brain could yield significant benefits over radiotherapy of the primary tumor mass alone and that damage caused by smaller fractions of radiation maybe less efficiently detected by the DNA repair mechanisms in CSCs.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Brain Stem Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Biol. 1999 Nov;75(11):1341-8 [10597908.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Sep;135(9):1239-44 [19277712.001]
  • [Cites] Radiother Oncol. 2002 Sep;64(3):259-73 [12242114.001]
  • [Cites] J Comp Neurol. 2003 Apr 14;458(4):381-8 [12619072.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):33-40 [12672027.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Brain Res. 2004 Jan 23;996(2):213-26 [14697499.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):103-8 [1309203.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] J Neurosci. 1992 Nov;12(11):4565-74 [1432110.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11879-83 [8524867.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3 [9574634.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Novartis Found Symp. 2005;265:66-80; discussion 82-97 [16050251.001]
  • [Cites] Cell Death Differ. 2006 Jul;13(7):1238-41 [16456578.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85 [17179479.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):978-85 [17467925.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] EMBO J. 2009 Jan 7;28(1):8-20 [19037256.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Am J Clin Oncol. 2009 Feb;32(1):20-2 [19194118.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1275-9 [19188675.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):459-66 [19269895.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:421-6 [19022744.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • (PMID = 20663133.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA137110; United States / NCI NIH HHS / CA / R01CA137110-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2918578
  •  go-up   go-down


53. Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T: O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol; 2010 Aug;15(4):352-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
  • OBJECTIVE: The prognostic significance of O(6)-methylguanine DNA methyltransferase (MGMT) was evaluated by analysis of both MGMT promoter methylation and protein expression in a series of patients with newly diagnosed glioblastoma.
  • CONCLUSIONS: Low MGMT expression and MGMT promoter methylation are both predictive markers for slower tumor progression in patients with glioblastoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / enzymology. DNA Methylation. DNA Modification Methylases / analysis. DNA Repair Enzymes / analysis. Glioblastoma / enzymology. Immunohistochemistry. Promoter Regions, Genetic. Tumor Suppressor Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Cranial Irradiation. Disease-Free Survival. Female. Humans. Japan. Kaplan-Meier Estimate. Male. Middle Aged. Neurosurgical Procedures. Polymerase Chain Reaction. Proportional Hazards Models. Radiotherapy, Adjuvant. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2007 Oct;130(Pt 10):2596-606 [17785346.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1461-8 [12684420.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12 ):3851-7 [9850030.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4189-99 [18757334.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12 ):1470-5 [17442989.001]
  • [Cites] J Neurosurg. 1993 May;78(5):767-75 [8468607.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):219-26 [15309911.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10 (15):4933-8 [15297393.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):506-9 [3418382.001]
  • [Cites] Neurol Res. 2003 Apr;25(3):241-8 [12739231.001]
  • [Cites] Brain Pathol. 2008 Oct;18(4):520-32 [18400046.001]
  • [Cites] Acta Neuropathol. 2008 Feb;115(2):249-59 [17965865.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] J Neurosurg. 1960 Jul;17:736-50 [14439403.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):59-65 [18091318.001]
  • [Cites] Neurosurgery. 1993 May;32(5):716-20; discussion 720 [8388081.001]
  • [Cites] Lab Invest. 2007 Oct;87(10 ):1055-65 [17700563.001]
  • [Cites] Acta Neurochir (Wien). 2009 Nov;151(11):1349-58 [19730774.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10 (6):1871-4 [15041700.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):61-4 [9525826.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):581-7 [15455376.001]
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] Neurosurgery. 2004 Feb;54(2):349-57; discussion 357 [14744281.001]
  • [Cites] Carcinogenesis. 1996 Apr;17(4):637-41 [8625471.001]
  • [Cites] Neurosurgery. 2009 Nov;65(5):866-75; discussion 875 [19834398.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5612-9 [9271436.001]
  • [Cites] J Neurooncol. 2007 Jun;83(2):173-9 [17219056.001]
  • [Cites] Neuropathology. 2009 Aug;29(4):379-88 [19019175.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer Genomics Proteomics. 2009 Jul-Aug;6(4):219-27 [19656999.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):275-83 [15332332.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Jpn J Clin Oncol. 2007 Dec;37(12 ):897-906 [18156172.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):333-40 [15662974.001]
  • (PMID = 20232102.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


54. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell; 2007 Feb;11(2):147-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TGFbeta acts as a tumor suppressor in normal epithelial cells and early-stage tumors and becomes an oncogenic factor in advanced tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Infant. Middle Aged. Oligonucleotide Array Sequence Analysis. Phosphorylation. Prognosis. Receptors, Transforming Growth Factor beta / metabolism. Signal Transduction. Smad7 Protein / metabolism. Survival Rate. Tumor Cells, Cultured


55. Al-Barbarawi MM, Qudsieh SM, Ghazzawi MA, Smith SF: Glioblastoma multiforme of the cerebellum. Neurosciences (Riyadh); 2009 Jan;14(1):84-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme of the cerebellum.
  • Glioblastoma multiforme (GBM) is a highly malignant glial tumor seen commonly in the cerebral hemispheres, but rarely encountered in the cerebellum.
  • It may occur at any age, but is seen more often in adult age groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048582.001).
  • [ISSN] 1319-6138
  • [Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)
  • [ISO-abbreviation] Neurosciences (Riyadh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


56. Amini A, Schmidt RH, Salzman KL, Chin SS, Couldwell WT: Glioblastoma multiforme of the pineal region. J Neurooncol; 2006 Sep;79(3):307-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme of the pineal region.
  • Glioblastoma multiforme (GBMs) tumors are exceedingly rare tumors in the pineal region.
  • Pineal region GBM seems to be a very aggressive tumor with a high rate of leptomeningeal and ependymal metastatic disease.
  • Glioblastoma should be considered in the differential diagnosis of the pineal region tumors, especially when evidence of leptomeningeal or ependymal metastatic disease is present.
  • [MeSH-major] Brain / pathology. Glioblastoma / pathology. Pinealoma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nausea / etiology. Tomography, X-Ray Computed. Vision Disorders / etiology. Vomiting / etiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] Arch Neurol. 1979 Nov;36(11):717-8 [508133.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):53-8 [9548342.001]
  • [Cites] Childs Nerv Syst. 1993 Nov;9(7):422-4 [8306360.001]
  • [Cites] Radiology. 1972 May;103(2):399-406 [4537183.001]
  • [Cites] Surg Neurol. 1985 Mar;23 (3):275-80 [3883555.001]
  • [Cites] Cancer. 1981 Feb 1;47(3):592-6 [6261912.001]
  • [Cites] Pediatr Neurosurg. 2003 Jun;38(6):307-23 [12759510.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):221-36 [15527093.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Jun;61(2B):468-72 [12894287.001]
  • [Cites] J Clin Neurosci. 2005 Sep;12(7):834-7 [16198924.001]
  • [Cites] J Neurosurg. 1973 Oct;39(4):455-62 [4730334.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):239-49 [11767290.001]
  • [Cites] J Neurosurg Sci. 1990 Apr-Jun;34(2):149-50 [1965444.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 16645719.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Gousias K, Markou M, Voulgaris S, Goussia A, Voulgari P, Bai M, Polyzoidis K, Kyritsis A, Alamanos Y: Descriptive epidemiology of cerebral gliomas in northwest Greece and study of potential predisposing factors, 2005-2007. Neuroepidemiology; 2009;33(2):89-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To investigate the epidemiologic and clinical characteristics (age, sex, tumor location, socioeconomic status) and potential predisposing factors (alcohol, tobacco, mobile phone use, severe head trauma) of cerebral gliomas in a defined area of Northwest Greece.
  • RESULTS: A total of 56 glioma incident cases were identified with IRs of glioma and glioblastoma (GBM) at 5.73/10(5)/year and 3.69/10(5)/year, respectively.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioma / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking / epidemiology. Brain / pathology. Causality. Cell Phones. Craniocerebral Trauma / epidemiology. Female. Greece / epidemiology. Humans. Male. Middle Aged. Rural Population. Sex Factors. Smoking / epidemiology. Social Class. Urban Population. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19494549.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


58. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH: Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res; 2006 Mar 15;66(6):3294-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Such restored immune function may give license to physiologic antiglioma activity, as in vivo, T(reg) depletion proves permissive for spontaneous tumor rejection in a murine model of established intracranial glioma.
  • These findings dramatically alter our understanding of depressed cellular immune function in patients with malignant glioma and advance a role for T(regs) in facilitating tumor immune evasion in the central nervous system.
  • [MeSH-major] Brain Neoplasms / immunology. CD4-Positive T-Lymphocytes / immunology. Glioblastoma / immunology. T-Lymphocyte Subsets / immunology
  • [MeSH-minor] Adult. Aged. Forkhead Transcription Factors / immunology. Humans. Lymphocyte Activation. Middle Aged. Th2 Cells / immunology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540683.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA108786; United States / NCI NIH HHS / CA / R01 CA09722; United States / NIGMS NIH HHS / GM / T32 GM-07171
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


59. Selkirk SM, Morrow J, Barone TA, Hoffer A, Lock J, DeChant A, Mangla S, Plunkett RJ, Miller RH: Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal. J Neurooncol; 2008 Feb;86(3):285-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal.
  • Osteopontin (OPN) is a pleotrophic molecule that has been associated with multiple disorders of the central nervous system (CNS).
  • Its roles in CNS malignancy are unclear but suggest that higher levels of OPN expression correlate with increased tumor grade and increased migratory capacity of tumor cells.
  • In this study OPN cDNA was cloned into a retroviral vector and used to infect F98 Fischer rat-derived glioma cells and U87 human-derived glioblastoma multiforme (GBM) cells in vitro.
  • Implantation of tumor cells expressing high levels of OPN into adult Fischer rats and nude rats resulted in morphologically distinct tumors and prolonged host survival relative to controls.
  • We propose that local produced, high level OPN expression limits the malignant character of glioma cells and that the downstream mechanisms involved represent pathways that may have therapeutic value in the treatment of human CNS malignancy.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36328-34 [10593924.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10024-31 [17047065.001]
  • [Cites] Exp Cell Res. 2000 Aug 1;258(2):342-51 [10896785.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24565-74 [10835423.001]
  • [Cites] Int J Exp Pathol. 2000 Dec;81(6):373-90 [11298186.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28261-7 [11375993.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1731-5 [11721059.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46024-30 [11590166.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] QJM. 2002 Jan;95(1):3-13 [11834767.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5336-43 [12235004.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6318-22 [12414663.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1198-205 [12606946.001]
  • [Cites] J Neuroimmunol. 2003 Mar;136(1-2):125-9 [12620651.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28593-606 [12771144.001]
  • [Cites] Mol Cancer Res. 2003 Sep;1(11):810-9 [14517343.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11051-64 [14704150.001]
  • [Cites] J Neuroimmunol. 2004 Oct;155(1-2):155-60 [15342207.001]
  • [Cites] Cell. 1979 Apr;16(4):885-93 [88265.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2900-7 [3469201.001]
  • [Cites] J Biol Chem. 1987 Jul 15;262(20):9702-8 [3597437.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):145-61 [2787378.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):426-30 [1729712.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Biochem J. 1994 Oct 1;303 ( Pt 1):255-62 [7945249.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] J Clin Invest. 1995 Feb;95(2):713-24 [7532190.001]
  • [Cites] Lung Cancer. 1996 Nov;15(3):311-23 [8959677.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):10110-6 [9092556.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):578-84 [9199622.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):219-26 [9892210.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:92-102 [9893260.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):19381-92 [15757900.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6638-48 [16818637.001]
  • [Cites] Bioessays. 2006 Sep;28(9):923-34 [16937364.001]
  • [Cites] Ann N Y Acad Sci. 1999;890:204-22 [10668427.001]
  • (PMID = 17928956.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA10373602; United States / NINDS NIH HHS / NS / R01 NS036674; United States / NINDS NIH HHS / NS / NS030800-14; United States / NINDS NIH HHS / NS / R01 NS030800; United States / NINDS NIH HHS / NS / NS-3080011; United States / NINDS NIH HHS / NS / R37 NS036674; United States / NINDS NIH HHS / NS / R01 NS030800-14; United States / NINDS NIH HHS / NS / NS-36674-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 106441-73-0 / Osteopontin; 147336-22-9 / Green Fluorescent Proteins; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ NIHMS196650; NLM/ PMC2911624
  •  go-up   go-down


60. Wrensch M, Kelsey KT, Liu M, Miike R, Moghadassi M, Sison JD, Aldape K, McMillan A, Wiemels J, Wiencke JK: ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol; 2005 Oct;7(4):495-507
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERCC1 and ERCC2 polymorphisms and adult glioma.
  • We genotyped constitutive variants ERCC1 C8092A and ERCC2 K751Q and R156R in approximately 450 adults with glioma and 500 controls from two independent population-based series, uniformly reviewed patients' tumors to determine histopathologic category, and determined a variety of tumor markers among astrocytic tumors.
  • Odds ratios (ORs) for glioblastoma for those carrying two ERCC1 A alleles versus none or one were 1.67 in series 1 and 1.64 in series 2, which yielded a combined OR of 1.67 (95% CI, 0.93-3.02; P = 0.09), adjusted for age, gender, ethnicity, and series.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Mol Genet Genomics. 2001 Aug;265(6):1087-96 [11523781.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):295-9 [11872635.001]
  • [Cites] Genome Res. 2002 Mar;12(3):436-46 [11875032.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1377-81 [11888908.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Carcinogenesis. 2002 Apr;23(4):599-603 [11960912.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 15;32(12):1244-53 [12057762.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):123-9 [12399122.001]
  • [Cites] Mutagenesis. 2002 Nov;17(6):463-9 [12435843.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 [12496039.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):359-65 [12692111.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):669-73 [12740916.001]
  • [Cites] J Occup Environ Med. 2003 Jun;45(6):639-47 [12802217.001]
  • [Cites] Nature. 2003 Jul 10;424(6945):228-32 [12853965.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):333-7 [12865926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):461-7 [15006924.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2251-7 [15026370.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):65-73 [15199548.001]
  • [Cites] Toxicol Lett. 2004 Dec 1;154(1-2):133-42 [15475187.001]
  • [Cites] Carcinogenesis. 1984 Apr;5(4):511-4 [6705149.001]
  • [Cites] Biochemistry. 1989 Oct 3;28(20):7979-84 [2690930.001]
  • [Cites] J Bacteriol. 1991 Jun;173(11):3419-24 [1710617.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] Chromosoma. 1997 Dec;106(8):493-502 [9426281.001]
  • [Cites] Yeast. 1999 Feb;15(3):205-18 [10077187.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2929-35 [10082560.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):345-50 [10209947.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):267-75 [15637390.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):45-54; quiz 57 [15661686.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):969-76 [15824172.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):44-50 [10708517.001]
  • [Cites] Cancer Lett. 2000 Apr 14;151(2):187-92 [10738113.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):551-5 [10753184.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):843-7 [10952103.001]
  • [Cites] Carcinogenesis. 2000 Dec;21(12):2219-23 [11133811.001]
  • [Cites] Lupus. 2000;9(9):681-7 [11199923.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1354-7 [11245433.001]
  • [Cites] Environ Mol Mutagen. 2001;37(3):241-83 [11317342.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60 [11319176.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3949-54 [11358811.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):911-2 [11489761.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):159-66 [11850545.001]
  • (PMID = 16212814.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA052689; United States / NCI NIH HHS / CA / P50CA097257; United States / NCI NIH HHS / CA / R01CA52689
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  • [Other-IDs] NLM/ PMC1871723
  •  go-up   go-down


61. Ma JH, Kim HS, Rim NJ, Kim SH, Cho KG: Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions. AJNR Am J Neuroradiol; 2010 Oct;31(9):1699-706
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions.
  • BACKGROUND AND PURPOSE: The histogram method has been shown to demonstrate heterogeneous morphologic features of tumor vascularity.
  • This study aimed to determine whether whole-tumor histogram analysis of the normalized CBV for contrast-enhancing lesions and perienhancing lesions can differentiate among GBMs, SMTs, and lymphomas.
  • Histogram distribution of the normalized CBV was obtained from whole-tumor voxels in contrast-enhancing lesions and perienhancing lesions.
  • One-way ANOVA was used initially to test the overall equality of mean values for each type of tumor.
  • RESULTS: For whole-tumor histogram analyses for contrast-enhancing lesions, only PHP could differentiate among GBMs (4.79 ± 1.31), SMTs (3.32 ± 1.10), and lymphomas (2.08 ± 0.54).
  • CONCLUSIONS: Using a whole-tumor histogram analysis of normalized CBV for contrast-enhancing lesions and perienhancing lesions facilitates differentiation of GBMs, SMTs and lymphomas.
  • [MeSH-major] Blood Volume Determination / methods. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Glioblastoma / diagnosis. Glioblastoma / secondary. Lymphoma / diagnosis. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Lymphatic Metastasis. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581063.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Cher L, Rosenthal MA, Drummond KJ, Dally M, Murphy M, Ashley D, Thursfield V, Giles GG: The use of chemotherapy in patients with gliomas: patterns of care in Victoria from 1998-2000. J Clin Neurosci; 2008 Apr;15(4):398-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, chemotherapy provides survival and quality of life benefits in the setting of recurrent high-grade gliomas and in patients with newly diagnosed glioblastoma multiforme.
  • [MeSH-minor] Adult. Australia / epidemiology. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18249119.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


63. Fahrner A, Kann G, Flubacher A, Heinrich C, Freiman TM, Zentner J, Frotscher M, Haas CA: Granule cell dispersion is not accompanied by enhanced neurogenesis in temporal lobe epilepsy patients. Exp Neurol; 2007 Feb;203(2):320-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Blotting, Western. Brain Neoplasms / pathology. Cell Nucleus / metabolism. Child. Dentate Gyrus / growth & development. Dentate Gyrus / pathology. Female. Glial Fibrillary Acidic Protein / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Infant. Ki-67 Antigen / immunology. Male. Microtubule-Associated Proteins / biosynthesis. Middle Aged. Mitosis / physiology. Neuroglia / physiology. Neurons / physiology. Neuropeptides / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Vimentin / metabolism

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17049346.001).
  • [ISSN] 0014-4886
  • [Journal-full-title] Experimental neurology
  • [ISO-abbreviation] Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neuropeptides; 0 / Vimentin; 0 / doublecortin protein
  •  go-up   go-down


64. Pyrko P, Schönthal AH, Hofman FM, Chen TC, Lee AS: The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res; 2007 Oct 15;67(20):9809-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here that GRP78 is expressed at low levels in normal adult brain, but is significantly elevated in malignant glioma specimens and human malignant glioma cell lines, correlating with their rate of proliferation.
  • Knockdown of GRP78 in glioblastoma cell lines induces CHOP and activates caspase-7 in temozolomide-treated cells.
  • These results identify a novel chemoresistance mechanism in malignant gliomas and show that combination of drugs capable of suppressing GRP78 with conventional agents such as temozolomide might represent a novel approach to eliminate residual tumor cells after surgery and increase the effectiveness of malignant glioma chemotherapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / metabolism. Glioblastoma / drug therapy. Glioblastoma / metabolism. Heat-Shock Proteins / antagonists & inhibitors. Heat-Shock Proteins / biosynthesis. Molecular Chaperones / antagonists & inhibitors. Molecular Chaperones / biosynthesis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Caspase 7 / metabolism. Catechin / administration & dosage. Catechin / analogs & derivatives. Catechin / pharmacology. Cell Growth Processes / physiology. Cell Line, Tumor. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Dacarbazine / pharmacology. Down-Regulation. Drug Screening Assays, Antitumor. Drug Synergism. Fluorouracil / administration & dosage. Fluorouracil / pharmacology. Humans. RNA, Small Interfering / genetics. Transcription Factor CHOP / biosynthesis. Transfection

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942911.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA027607; United States / NCI NIH HHS / CA / CA111700
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DDIT3 protein, human; 0 / Heat-Shock Proteins; 0 / Molecular Chaperones; 0 / RNA, Small Interfering; 0 / molecular chaperone GRP78; 147336-12-7 / Transcription Factor CHOP; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 3.4.22.- / Caspase 7; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


65. Ogawa K, Yoshii Y, Inoue O, Toita T, Saito A, Kakinohana Y, Adachi G, Iraha S, Tamaki W, Sugimoto K, Hyodo A, Murayama S: Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas. Br J Cancer; 2006 Oct 9;95(7):862-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.
  • We conducted a phase II trial to evaluate the efficacy and toxicity of radiotherapy immediately after hyperbaric oxygenation (HBO) with chemotherapy in adults with high-grade gliomas.
  • Patients with histologically confirmed high-grade gliomas were administered radiotherapy in daily 2 Gy fractions for 5 consecutive days per week up to a total dose of 60 Gy.
  • A total of 41 patients (31 patients with glioblastoma and 10 patients with grade 3 gliomas) were enrolled.
  • The median time to progression and the median survival time in glioblastoma patients were 12.3 months and 17.3 months, respectively.
  • On univariate analysis, histologic grade (P=0.0001) and Karnofsky performance status (P=0.036) had a significant impact on survival, and on multivariate analysis, histologic grade alone was a significant prognostic factor for survival (P=0.001).
  • Although grade 4 leukopenia and grade 4 thrombocytopenia occurred in 10 and 7% of all patients, respectively, these were transient with no patients developing neutropenic fever or intracranial haemorrhage.
  • These results indicated that radiotherapy delivered immediately after HBO with chemotherapy was safe with virtually no late toxicity in patients with high-grade gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Glioma / therapy. Hyperbaric Oxygenation. Radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Nimustine / administration & dosage. Procarbazine / administration & dosage. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jan;82(1):88-92 [10638972.001]
  • [Cites] J Neurooncol. 1999 Jun;43(2):161-6 [10533728.001]
  • [Cites] Cancer Lett. 2001 Mar 26;164(2):149-54 [11179829.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1037-44 [11704328.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] J Neurooncol. 2002 May;58(1):47-52 [12160140.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):151-5 [12241108.001]
  • [Cites] Radiother Oncol. 2002 Sep;64(3):259-73 [12242114.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):161-70 [12622455.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):171-6 [12635665.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1485-91 [12697871.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):63-7 [12758241.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Lancet. 1977 Jul 16;2(8029):101-3 [69191.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):649-52 [6164465.001]
  • [Cites] Neuroradiology. 1982;23(2):63-74 [6979003.001]
  • [Cites] J Nucl Med. 1987 Jul;28(7):1123-33 [3496433.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):55-9 [1984507.001]
  • [Cites] Radiother Oncol. 1991;20 Suppl 1:71-4 [2020772.001]
  • [Cites] Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):903-5 [1327243.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer. 1994 May 1;73(9):2386-94 [8168042.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):427-31 [8005794.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • [Cites] J Natl Cancer Inst Monogr. 1996;(21):105-12 [9023838.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):535-43 [10348282.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):236-41 [10390002.001]
  • [Cites] J Appl Physiol. 1963 Sep;18:869-76 [14063253.001]
  • [Cites] Strahlenther Onkol. 2005 Feb;181(2):113-23 [15702300.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Med Sci Monit. 2005 Sep;11(9):RA279-89 [16127374.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(4):CD005007 [16235387.001]
  • [Cites] Radiother Oncol. 1999 Nov;53(2):127-31 [10665789.001]
  • (PMID = 16953239.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0S726V972K / Nimustine; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine
  • [Other-IDs] NLM/ PMC2360529
  •  go-up   go-down


66. Kawai N, Kagawa M, Hatakeyama T, Tamiya T, Noshiyama Y, Yamamoto Y, Miki A, Ichikawa T: [11C-methionine positron emission tomography in brain tumor]. No Shinkei Geka; 2008 Oct;36(10):847-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C-methionine positron emission tomography in brain tumor].
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Methionine. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Astrocytoma / therapy. Glioblastoma / pathology. Glioblastoma / radionuclide imaging. Glioblastoma / therapy. Humans. Middle Aged. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / therapy. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18975560.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  • [Number-of-references] 58
  •  go-up   go-down


67. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T, ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery; 2008 Mar;62(3):564-76; discussion 564-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.
  • OBJECTIVE: The influence of the degree of resection on survival in patients with glioblastoma multiforme is still under discussion.
  • METHODS: Two hundred forty-three patients with glioblastoma multiforme per protocol from the 5-aminolevulinic acid study were analyzed.
  • Prognostic factors that might cause bias regarding resection and influence survival (e.g., tumor size, edema, midline shift, location, age, Karnofsky Performance Scale score, National Institutes of Health Stroke Scale score) were used for analysis of overall survival.
  • RESULTS: Treatment bias was identified in patients with complete (n = 122) compared with incomplete resection (n = 121), i.e., younger age and less frequent eloquent tumor location.
  • Other factors, foremost preoperative tumor size, were identical.
  • Patients without residual tumor survived longer (16.7 versus 11.8 mo, P < 0.0001).
  • In multivariate analysis, only residual tumor, age, and Karnofsky Performance Scale score were significantly prognostic.
  • Reinterventions occurred marginally earlier in patients with residual tumor (6.7 versus 9.5 mo, P = 0.0582).
  • However, bias and imbalances were controllable in the cohorts available from the 5-aminolevulinic acid study so that the present data now provide Level 2b evidence (Oxford Centre for Evidence-based Medicine) that survival depends on complete resection of enhancing tumor in glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Glioblastoma / mortality. Glioblastoma / surgery. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Bias (Epidemiology). Disease-Free Survival. Female. Germany / epidemiology. Humans. Male. Middle Aged. Prevalence. Reproducibility of Results. Risk Assessment. Risk Factors. Sensitivity and Specificity. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurgery. 2009 Jun;64(6):E1206; author reply E1206 [19487874.001]
  • (PMID = 18425006.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Oppel F; Brune A; Lanksch W; Woiciechowsky C; Brock M; Vesper J; Tonn JC; Goetz C; Gilsbach JM; Mayfrank L; Oertel MF; Seifert V; Franz K; Bink A; Schackert G; Pinzer T; Hassler W; Bani A; Meisel HJ; Kern BC; Mehdorn HM; Nabavi A; Brawanski A; Ullrich OW; Böker DK; Winking M; Weber F; Langenbach U; Westphal M; Kähler U; Arnold H; Knopp U; Grumme T; Stretz T; Stolke D; Wiedemayer H; Turowski B; Pietsch T; Wiestler OD; Reulen HJ; Stummer W
  •  go-up   go-down


68. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards JB, Eberhart C, Murphy KM, Tsiamouri A, Beeson K, Simpson AJ, Venter JC, Riggins GJ, Strausberg RL: Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A; 2005 Oct 4;102(40):14344-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report on the sequence analysis of members of the receptor tyrosine kinase (RTK) gene family in the genomes of glioblastoma brain tumors.
  • Previous studies have identified a number of molecular alterations in glioblastoma, including amplification of the RTK epidermal growth factor receptor.
  • [MeSH-major] Brain Neoplasms / genetics. Evolution, Molecular. Glioblastoma / genetics. Models, Molecular. Mutation / genetics. Receptor Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Amino Acid Sequence. Base Sequence. Child. Female. Genomics / methods. Humans. Male. Models, Genetic. Molecular Sequence Data. Receptor, Fibroblast Growth Factor, Type 1 / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16156-61 [12461184.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):84-7 [9425908.001]
  • [Cites] Oncogene. 2003 Feb 6;22(5):722-33 [12569364.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):29-36 [14603439.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94 [14970324.001]
  • [Cites] Adv Cancer Res. 2004;91:1-30 [15327887.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5 Suppl 10):51-7 [15490375.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8602-6 [2236070.001]
  • [Cites] FEBS Lett. 1991 Aug 19;288(1-2):65-71 [1652481.001]
  • [Cites] Oncogene. 1992 Apr;7(4):627-33 [1314366.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • [Cites] Mol Cell Biol. 1993 Dec;13(12):7203-12 [8246942.001]
  • [Cites] Hum Mutat. 1998;Suppl 1:S62-5 [9452043.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Biol Chem. 1998 Dec 25;273(52):35250-9 [9857065.001]
  • [Cites] Protein Sci. 1999 Mar;8(3):676-9 [10091670.001]
  • [Cites] Hum Mutat. 1999;14(2):115-25 [10425034.001]
  • [Cites] Glia. 1999 Oct;28(1):66-76 [10498824.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1283-316 [10508235.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):945-8 [15558020.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):27-34 [15696966.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49 [15863030.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):187-203 [15863034.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):590-2 [15908952.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5357-64 [15928335.001]
  • [Cites] J Pathol. 2005 Oct;207(2):224-31 [16021678.001]
  • [Cites] J Mol Biol. 1993 Dec 5;234(3):779-815 [8254673.001]
  • [Cites] J Cell Physiol. 1994 Feb;158(2):381-9 [8106574.001]
  • [Cites] J Neurooncol. 1994;18(3):207-16 [7964981.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7033-6 [7706238.001]
  • [Cites] Nat Genet. 1995 Jul;10(3):357-9 [7670477.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):164-71 [8548759.001]
  • [Cites] Methods Enzymol. 1996;266:383-402 [8743695.001]
  • [Cites] Cell. 1996 Aug 23;86(4):577-87 [8752212.001]
  • [Cites] Science. 1997 May 9;276(5314):955-60 [9139660.001]
  • [Cites] J Med Genet. 2000 Mar;37(3):220-4 [10777366.001]
  • [Cites] J Mol Diagn. 2000 Feb;2(1):20-8 [11272898.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):472-86 [11781872.001]
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):111-5 [11790564.001]
  • [Cites] Hum Mol Genet. 2002 Jun 1;11(12):1391-7 [12023981.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):416-27 [12112531.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1912-34 [12471243.001]
  • [Cites] Trends Genet. 1997 May;13(5):178-82 [9154000.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Trends Biochem Sci. 1997 Nov;22(11):444-6 [9397688.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • (PMID = 16186508.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ PMC1242336
  •  go-up   go-down


69. Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res; 2009 Mar;29(3):911-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of temozolomide treatment in patients with high-grade glioma.
  • BACKGROUND: Numerous studies have reported the clinical efficacy of temozolomide (TMZ) treatment for high-grade glioma, but information on Japanese populations has been limited.
  • PATIENTS AND METHODS: The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n=3, gliosarcoma (GS), n=1, anaplastic oligodendroglioma (AO), n=3, anaplastic mixed oligoastrocytoma (AOA), n=1, and anaplastic ependymoma (AE), n=2].
  • As second- or third-line chemotherapy, patients received TMZ for recurrence or tumor progression.
  • As combination therapy, the local administration of tumor necrosis factor-alpha and the addition of carboplatin and etoposide were included for three patients during the course of oral TMZ treatment.
  • One of the patients receiving combination therapy has continued to show shrinkage of the relapsed tumor.
  • Despite prior radio- and chemotherapy, most patients experienced only grade 1-2 hematotoxicity that was well-controlled by conservative therapy.
  • CONCLUSION: TMZ chemotherapy is effective for the treatment of high-grade glioma in some patients without serious toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Treatment Outcome. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414327.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


70. Khasraw M, Bell D, Wheeler H: Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci; 2009 Jun;16(6):854-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Drug-Related Side Effects and Adverse Reactions. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain / drug effects. Brain / pathology. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / prevention & control. Neurosurgical Procedures / methods. Radiotherapy / methods. Retrospective Studies. Time. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303779.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


71. Ulmer S, Liess C, Kesari S, Otto N, Straube T, Jansen O: Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. J Neurooncol; 2009 Jan;91(2):213-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma.
  • INTRODUCTION: We investigated the effect of increased tumor perfusion using dynamic susceptibility-contrast magnetic resonance imaging (DSC-MRI) in glioblastoma (GBM) patients on the surrounding ipsilateral brain tissue with respect to perfusion of the normal, unaffected contralateral brain and of the tumor.
  • MATERIAL AND METHODS: DSC-MRI was performed in 11 patients with glioblastoma using a multislice T2*-weighed EPI sequence (TR/TE = 2,000/62 ms; FOV 240 mm; matrix 128 x 128; slice thickness 6 mm) on a standard clinical 1.5 Tesla scanner during intravenous injection of 40 cc Gadolinium-DTPA at a flow rate of 5 cc/s.
  • RESULTS: Relative CBV and CBF were significantly higher in gray matter than in the respective white matter (paired t-test; P < 0.001) with a high correlation for both perfusion parameters between the gray and the white matter in both ipsilateral and contralateral brain (P < 0.001).
  • The highest values for rCBV and rCBF were found in solid tumor tissue with a significant positive correlation between tumor and the adjacent gray matter (for both rCBV and rCBF; P < 0.001).
  • CONCLUSION: In GBM patients there is increased metabolism and thus increased rCBV and rCBF within the tumor.
  • This increased perfusion of the tumor is not at the expense of perfusion of the ipsilateral normal brain parenchyma and in fact, the rCBV and rCBF values are linked to tumor-induced changes in rCBV and rCBF.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Connective Tissue / pathology. Functional Laterality. Glioblastoma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cerebrovascular Circulation. Contrast Media. Female. Humans. Male. Middle Aged. Perfusion

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):881-90 [10815664.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Adv Exp Med Biol. 2003;530:347-57 [14562730.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] Acad Radiol. 2001 May;8(5):384-91 [11345268.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Magn Reson Med. 2000 Jun;43(6):845-53 [10861879.001]
  • [Cites] Neuroimage. 2005 Jan 1;24(1):1-11 [15588591.001]
  • [Cites] J Cancer Res Clin Oncol. 1991;117(5):396-402 [1716257.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):891-9 [10815665.001]
  • [Cites] J Magn Reson Imaging. 2005 Dec;22(6):697-703 [16261571.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):300-5 [9950501.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):156-65 [16533757.001]
  • [Cites] Histopathology. 2001 Oct;39(4):409-15 [11683943.001]
  • [Cites] Radiology. 2006 Feb;238(2):658-67 [16396838.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):53-8 [10924971.001]
  • [Cites] Radiology. 1988 Mar;166(3):823-7 [2829270.001]
  • [Cites] Magn Reson Imaging. 1985;3(1):27-35 [2987640.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] J Magn Reson Imaging. 2005 Dec;22(6):710-7 [16261573.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Radiology. 2002 Mar;222(3):715-21 [11867790.001]
  • [Cites] Radiology. 1999 Feb;210(2):519-27 [10207439.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):711-6 [11856703.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):353-7; discussion 357-8 [11220379.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neuroradiology. 2002 Oct;44(10):806-11 [12389127.001]
  • [Cites] J Magn Reson Imaging. 2005 Dec;22(6):718-22 [16261569.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):402-8 [16484419.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):134-45 [12784879.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Neuroimage. 2006 Aug 15;32(2):489-97 [16806983.001]
  • [Cites] J Magn Reson Imaging. 2005 Dec;22(6):693-6 [16261568.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67 [16611779.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • (PMID = 18807224.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


72. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, Saltz JH, Brat DJ, Moreno CS: The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One; 2010 Sep 03;5(9):e12548
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Cancer Genome Atlas Project (TCGA) has produced an extensive collection of '-omic' data on glioblastoma (GBM), resulting in several key insights on expression signatures.
  • Despite the richness of TCGA GBM data, the absence of lower grade gliomas in this data set prevents analysis genes related to progression and the uncovering of predictive signatures.
  • A complementary dataset exists in the form of the NCI Repository for Molecular Brain Neoplasia Data (Rembrandt), which contains molecular and clinical data for diffuse gliomas across the full spectrum of histologic class and grade.
  • We demonstrate that the proneural signature predicts improved clinical outcome among 176 Rembrandt gliomas that includes all histologies and grades, including GBMs (log rank test p = 1.16e-6), but also among 75 grade II and grade III samples (p  =  2.65e-4).
  • This gene expression signature was enriched in tumors with oligodendroglioma histology and also predicted improved survival in this tumor type (n =  43, p  =  1.25e-4).
  • Thus, expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for lower grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy.
  • Integrated DNA and RNA analysis of low-grade and high-grade proneural gliomas identified increased expression and gene amplification of several genes including GLIS3, TGFB2, TNC, AURKA, and VEGFA in proneural GBMs, with corresponding loss of DLL3 and HEY2.
  • This demonstrates that the expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for low-grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 9;354(2):567-73 [17250806.001]
  • [Cites] Bioinformatics. 2007 Dec 1;23(23):3251-3 [17644558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] BMC Genomics. 2007;8:461 [18088408.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Mol Cancer Res. 2009 Feb;7(2):157-67 [19208739.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2091-9 [19244127.001]
  • [Cites] Oncogene. 2009 Oct 1;28(39):3468-76 [19617900.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):98-110 [20129251.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):837-49 [10879735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29399-405 [12050162.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] EMBO J. 1988 Oct;7(10):2977-82 [2460335.001]
  • [Cites] Am J Physiol. 1995 Feb;268(2 Pt 1):L173-80 [7532367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1962 Mar;87:473-9 [13919885.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Bioinformatics. 2006 Jan 1;22(1):122-3 [16269418.001]
  • [Cites] Blood. 2006 Feb 1;107(3):931-9 [16219802.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • (PMID = 20838435.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / PHS HHS / / S09-094; United States / NIBIB NIH HHS / EB / P20 EB000591; United States / NCATS NIH HHS / TR / UL1 TR000454; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NLM NIH HHS / LM / R01 LM011119
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2933229
  •  go-up   go-down


73. Habermeyer B, Weiland M, Mager R, Wiesbeck GA, Wurst FM: A clinical lesson: glioblastoma multiforme masquerading as depression in a chronic alcoholic. Alcohol Alcohol; 2008 Jan-Feb;43(1):31-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical lesson: glioblastoma multiforme masquerading as depression in a chronic alcoholic.
  • METHOD: We report the case of a 34-year-old male alcoholic, who presented with clinical depression and later a delirious state, and was subsequently diagnosed to have a right frontal glioblastoma multiforme.
  • [MeSH-major] Alcoholism / diagnosis. Brain Neoplasms / diagnosis. Depression / diagnosis. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male


74. Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg A, Mikkelsen T, Diasio RB, Zhang K, Allison D, Grizzle WE, Wang W, Gillespie GY, Johnson MR: Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol; 2006 Dec;80(3):261-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).
  • BACKGROUND: The limited success of empirically designed treatment paradigms for patients diagnosed with glioblastoma multiforme (GBM) emphasizes the need for rationally designed treatment strategies based on the molecular profile of tumor samples and their correlation to clinical parameters.
  • Non-neoplastic brain tissue (n = 5) was obtained from patients who underwent surgery for refractory epilepsy.
  • Sufficient RNA was available to use RTQ-LDA to quantify the expression of 93 independent genes in 5 LTS, 4 DOD, and 5 non-neoplastic brain samples.
  • Ribonucleotide reductase subunit M2 (RRM2) was identified as tumor-specific, but not associated with survival.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Endopeptidases / metabolism. Glioblastoma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Thymidylate Synthase / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Disease-Free Survival. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged. RNA / analysis. Retrospective Studies. Statistics, Nonparametric. Ubiquitin Thiolesterase

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14988-93 [12419851.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Oncology. 2002;63(2):185-91 [12239455.001]
  • [Cites] Mol Cell. 2005 Feb 4;17 (3):331-9 [15694335.001]
  • [Cites] Plant J. 2001 Sep;27(5):393-405 [11576424.001]
  • [Cites] Biochim Biophys Acta. 2004 Nov 29;1695(1-3):189-207 [15571815.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):180-7 [11801556.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] J Cell Mol Med. 2005 Apr-Jun;9(2):360-72 [15963255.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):108-16 [11771519.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):253-61 [15050917.001]
  • [Cites] Anticancer Drugs. 2005 Jan;16(1):1-9 [15613898.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6316-25 [14695130.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6702-11 [15273734.001]
  • [Cites] Int J Urol. 2002 Jul;9(7):368-76 [12165018.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1745-8 [14534892.001]
  • [Cites] Nature. 2002 Apr 11;416(6881):648-53 [11923872.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):76-83 [16436637.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S80-9 [12819937.001]
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] Mol Microbiol. 2003 Feb;47(4):871-7 [12581345.001]
  • [Cites] Oncology. 1994 Jul-Aug;51(4):334-8 [8208516.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8773-81 [16361565.001]
  • [Cites] Neurology. 2002 Apr 9;58(7):1109-12 [11940704.001]
  • [Cites] Neurol India. 2005 Sep;53(3):329-32 [16230803.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1077-83 [12569609.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • [Cites] Wien Klin Wochenschr. 2003 Jun 24;115(11):389-97 [12879737.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8581-9 [14634620.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Feb;308(2):434-7 [14610217.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Neurosurgery. 2005 Feb;56(2):242-8; discussion 242-8 [15670372.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):21-31 [12469181.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):70-7 [9428481.001]
  • [Cites] Med Electron Microsc. 2001 Dec;34(4):207-12 [11956993.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):1139-45 [12481438.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2802-11 [12782585.001]
  • [Cites] Ann Med. 2004;36(4):285-95 [15224655.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6562-6 [11983868.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2527-36 [11489836.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):421-4 [11474279.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1539-48 [14661056.001]
  • [Cites] Cancer J. 2003 May-Jun;9(3):214-21 [12952306.001]
  • (PMID = 16773218.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 097247
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 63231-63-0 / RNA; EC 2.1.1.45 / Thymidylate Synthase; EC 3.1.2.15 / USP10 protein, human; EC 3.4.- / Endopeptidases; EC 3.4.19.12 / Ubiquitin Thiolesterase
  •  go-up   go-down


75. Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson JJ: Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol; 2010 Oct;100(1):95-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 66 patients enrolled had a median age of 51 years, median KPS of 90%, and 77% had glioblastoma multiforme.
  • The MTD in the -EIASD group was 1.70 mg/m(2) based on grade 3 thrombocytopenia, sensory neuropathy and fatigue.
  • Some evidence of clinical activity was noted in this phase I study in patients with recurrent high grade gliomas.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Invest New Drugs. 2000 May;18(2):109-21 [10857991.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3719-28 [10999766.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3071-6 [11306489.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1419-28 [11350913.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):11-7 [11516199.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1083-6 [11861386.001]
  • [Cites] Clin Lymphoma. 2002 Jun;3(1):49-55 [12141956.001]
  • [Cites] Curr Oncol Rep. 2002 Sep;4(5):369-74 [12162909.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2505-11 [12171876.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4996-5000 [12208752.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4420-7 [12431963.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] Drug Metab Dispos. 2003 May;31(5):533-9 [12695340.001]
  • [Cites] Blood. 2003 Jul 1;102(1):303-10 [12637321.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3765-74 [12893773.001]
  • [Cites] Ann Pharmacother. 2003 Dec;37(12):1825-30 [14632585.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):115-9 [14701773.001]
  • [Cites] Drug Metab Dispos. 2004 Mar;32(3):348-58 [14977870.001]
  • [Cites] Health Phys. 2004 May;86(5 Suppl):S120-3 [15069303.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3371-6 [15161691.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2108-21 [15169797.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1886-9 [8083712.001]
  • [Cites] Immunity. 1995 May;2(5):493-506 [7538441.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1056-65 [8929495.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1652-9 [8939846.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4342-8 [9766662.001]
  • [Cites] Drug Metab Dispos. 2005 Jun;33(6):771-7 [15764713.001]
  • [Cites] Ann Clin Lab Sci. 2005 Summer;35(3):251-8 [16081580.001]
  • [Cites] Blood. 2005 Nov 1;106(9):2977-81 [16020506.001]
  • [Cites] Drug Metab Dispos. 2005 Nov;33(11):1723-8 [16103134.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3777-84 [16099887.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3113-20 [16754936.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1171-91 [17113458.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1516-22 [17332297.001]
  • [Cites] J Infus Nurs. 2007 Mar-Apr;30(2):113-8; quiz 121 [17413496.001]
  • [Cites] Br J Haematol. 2007 Jun;137(5):429-35 [17451408.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3403-12 [17545549.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3557-60 [17690257.001]
  • [Cites] Curr Opin Neurol. 2007 Dec;20(6):712-8 [17992095.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1537-60 [18020923.001]
  • [Cites] Bone Marrow Transplant. 2007 Dec;40(12):1129-37 [17768392.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1139-46 [18246536.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1446-54 [18316568.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4175-85 [18593997.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):608-16 [18577560.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Clin Chem. 2000 May;46(5):673-83 [10794750.001]
  • (PMID = 20213332.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01 CA-62475
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ NIHMS521311; NLM/ PMC3811025
  •  go-up   go-down


76. Laigle-Donadey F, Sanson M: [Pattern of care of high-grade gliomas]. Rev Prat; 2006 Oct 31;56(16):1779-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pattern of care of high-grade gliomas].
  • [Transliterated title] Prise en charge des gliomes de haut grade.
  • High grade gliomas are the most frequent and malignant primary brain tumours in adults.
  • Prognosis depends on age, performance status and histological grade.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / therapeutic use. Adult. Age Factors. Aged. Anticonvulsants / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Brain / pathology. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Epilepsy / prevention & control. Forecasting. Genetic Markers. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy. Prognosis. Quality of Life. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Survival Analysis. Thromboembolism / prevention & control. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315503.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anticonvulsants; 0 / Antineoplastic Agents, Alkylating; 0 / Genetic Markers; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 19
  •  go-up   go-down


77. Fischer U, Keller A, Leidinger P, Deutscher S, Heisel S, Urbschat S, Lenhof HP, Meese E: A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma. Mol Cancer Res; 2008 Apr;6(4):576-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To further understand the biological significance of amplifications for glioma development and recurrencies, we characterized amplicon frequency and size in low-grade glioma and amplicon stability in vivo in recurring glioblastoma.
  • We developed a 12q13-21 amplicon-specific genomic microarray and a bioinformatics amplification prediction tool to analyze amplicon frequency, size, and maintenance in 40 glioma samples including 16 glioblastoma, 10 anaplastic astrocytoma, 7 astrocytoma WHO grade 2, and 7 pilocytic astrocytoma.
  • Analyzing 40 glioma, we found that all analyzed glioblastoma and the majority of pilocytic astrocytoma, grade 2 astrocytoma, and anaplastic astrocytoma showed at least one amplified subregion, indicating a much higher amplification frequency than previously suggested.
  • Amplifications in low-grade glioma were smaller in size and displayed clearly different distribution patterns than amplifications in glioblastoma.
  • One glioblastoma and its recurrencies revealed an amplified subregion of 5 Mb that was stable for 6 years.
  • Our data indicate that amplifications on 12q13-21 (a) are more frequent than previously thought and present in low-grade tumors and (b) are maintained as extended regions over long periods of time.
  • [MeSH-major] Chromosomes, Human, Pair 12 / genetics. DNA, Neoplasm / genetics. Gene Amplification. Glioma / genetics
  • [MeSH-minor] Adult. Aged. Blotting, Southern. Carbocyanines. Child. Child, Preschool. Chromosomes, Artificial, Bacterial. Computational Biology. Cosmids. Female. Gene Expression Regulation, Neoplastic. Genes, Neoplasm. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403636.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbocyanines; 0 / DNA, Neoplasm; 0 / cyanine dye 3; 0 / cyanine dye 5
  •  go-up   go-down


78. Chaudhry MA, Sachdeva H, Omaruddin RA: Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways. DNA Cell Biol; 2010 Sep;29(9):553-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways.
  • The human glioma cell line M059J is deficient in DNA-dependent protein kinase (DNA-PK), whereas cell line M059K, isolated from the same malignant tumor, has normal DNA-PK activity.
  • DNA-PK plays a central role in the repair of ionizing-radiation-induced double-strand break repair, and its deficiency has been correlated with ionizing radiation sensitivity in these glioblastoma cells.
  • The contribution of miRNAs in mediating resistance of glioblastoma cell to ionizing radiation treatment has not been elucidated.
  • These results indicate the involvement of miRNAs in the differential response of glioblastoma cells to ionizing radiation treatment.
  • [MeSH-major] DNA Repair / genetics. DNA Repair / radiation effects. Gene Expression Regulation, Neoplastic / radiation effects. Glioblastoma / genetics. Glioblastoma / pathology. MicroRNAs / genetics. MicroRNAs / radiation effects
  • [MeSH-minor] Adult. Cell Line, Tumor. DNA Damage. Genes, myc / genetics. Humans. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380575.001).
  • [ISSN] 1557-7430
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / mirnlet7 microRNA, human
  •  go-up   go-down


79. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS Sr, Riggins GJ: PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res; 2006 Oct;4(10):709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
  • Recently, a large-scale mutational analysis of eight PI3K and eight PI3K-like genes revealed somatic mutations in PIK3CA, which encodes the p110alpha catalytic subunit of class IA PI3K, in several types of cancer, including glioblastoma multiforme.
  • Given this disparity and to address the relation of patient age to mutation frequency, we examined 10 exons of PIK3CA in 73 glioblastoma samples by PCR amplification followed by direct DNA sequencing.
  • Of the primary tumors, PIK3CA mutations were identified in 21% and 17% of pediatric and adult samples, respectively.
  • [MeSH-major] Genetic Predisposition to Disease. Glioblastoma / genetics. Mutation. Phosphatidylinositol 3-Kinases / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050665.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  •  go-up   go-down


80. Shetty PM, Moiyadi AV: Florid leptomeningeal dissemination in a case of glioblastoma multiforme. Neurol India; 2010 May-Jun;58(3):501-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Florid leptomeningeal dissemination in a case of glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adult. Craniotomy / methods. Humans. Lateral Ventricles / pathology. Magnetic Resonance Imaging / methods. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644297.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


81. Cecener G, Tunca B, Egeli U, Bekar A, Guler G, Tolunay S, Aksoy K: FHIT gene sequence variants and reduced Fhit protein expression in glioblastoma multiforme. Cell Mol Neurobiol; 2010 Mar;30(2):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FHIT gene sequence variants and reduced Fhit protein expression in glioblastoma multiforme.
  • Molecular studies have an important role in the elucidation of the mechanisms involved in Glioblastoma multiforme (GBM) development.
  • In conclusion, the reduction or loss of Fhit protein expression by genetic alterations or epigenetic mechanisms in GBM might be associated with brain tumorigenesis.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Acid Anhydride Hydrolases / metabolism. Genetic Variation. Glioblastoma / genetics. Glioblastoma / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Base Sequence. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Teratog Carcinog Mutagen. 1998;18(6):279-91 [10052563.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Head Neck. 2000 Sep;22(6):591-8 [10941161.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] Teratog Carcinog Mutagen. 2002;22(3):205-15 [11948631.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):281-9 [9559339.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Tumori. 2007 Nov-Dec;93(6):604-7 [18338497.001]
  • [Cites] J Neurooncol. 2007 May;82(3):263-9 [17151929.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):442-8 [8609556.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):27-36 [16225988.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):504-12 [9012482.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1435-7 [9108441.001]
  • [Cites] Oncol Rep. 1999 Mar-Apr;6(2):345-8 [10023002.001]
  • [Cites] Brain Res Brain Res Rev. 2004 Jul;45(3):143-63 [15210301.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):1031-5 [11029509.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Nucleic Acids Res. 2006 Mar 06;34(5):1317-25 [16522644.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1605-14 [15073846.001]
  • [Cites] Cell. 1996 Apr 5;85(1):17-26 [8620533.001]
  • [Cites] Tumori. 2007 Nov-Dec;93(6):597-603 [18338496.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jun;119(2):139-45 [10867150.001]
  • [Cites] Int J Cancer. 1998 Apr 13;76(2):176-81 [9537577.001]
  • [Cites] Nucleic Acids Res. 2005 Sep 07;33(16):5053-62 [16147989.001]
  • [Cites] Teratog Carcinog Mutagen. 2002;22(1):31-40 [11754385.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2638-41 [9205070.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jun;95(2):153-8 [9169033.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3664-8 [9288768.001]
  • [Cites] Ai Zheng. 2003 Jan;22(1):50-4 [12561436.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):214-21 [11902576.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2256-67 [9187130.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):748-54 [12473516.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33 [14734474.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • (PMID = 19760177.001).
  • [ISSN] 1573-6830
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


82. Maurage CA, Adam E, Minéo JF, Sarrazin S, Debunne M, Siminski RM, Baroncini M, Lassalle P, Blond S, Delehedde M: Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol; 2009 Jun;68(6):633-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In U118MG cells, tumor necrosis factor and fibroblast growth factor 2 upregulated endocan production, whereas exposure to hypoxia or cobalt chloride, an inducer of hypoxia inducible factor 1, increased endocan release without affecting cell viability.
  • Endocan expression in 82 brain tumors was studied by immunohistochemistry.
  • Endocan immunoreactivity was detected in hyperplastic endothelial cells in high-grade gliomas, mostly at the tumor margins; endothelial cells were mostly endocan negative in low-grade gliomas, and it was never detected in the cerebral cortex distant from the tumors.
  • Tumor cells in high-grade but not low-grade gliomas also expressed endocan, and it was detected in palisading cells surrounding areas of necrosis in GBM.
  • Taken together, these results suggest that endocan is associated with abnormal vasculature in high-grade gliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioblastoma / metabolism. Neoplasm Proteins / metabolism. Proteoglycans / metabolism
  • [MeSH-minor] Adult. Aged. Anoxia / metabolism. Anoxia / physiopathology. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis. Time Factors. Tumor Necrosis Factor-alpha / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458546.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ESM1 protein, human; 0 / Neoplasm Proteins; 0 / Proteoglycans; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


83. Veselska R, Kuglik P, Cejpek P, Svachova H, Neradil J, Loja T, Relichova J: Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer; 2006;6:32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in the cell lines derived from glioblastoma multiforme.
  • BACKGROUND: Nestin is a protein belonging to class VI of intermediate filaments that is produced in stem/progenitor cells in the mammalian CNS during development and is consecutively replaced by other intermediate filament proteins (neurofilaments, GFAP).
  • Down-regulated nestin may be re-expressed in the adult organism under certain pathological conditions (brain injury, ischemia, inflammation, neoplastic transformation).
  • Our work focused on a detailed study of the nestin cytoskeleton in cell lines derived from glioblastoma multiforme, because re-expression of nestin together with down-regulation of GFAP has been previously reported in this type of brain tumor.
  • METHODS: Two cell lines were derived from the tumor tissue of patients treated for glioblastoma multiforme.
  • RESULTS: Using epifluorescence and confocal microscopy, we described the morphology of nestin-positive intermediate filaments in glioblastoma cells of both primary cultures and the derived cell lines, as well as the reorganization of nestin during mitosis.
  • CONCLUSION: Detailed information concerning the pattern of the nestin cytoskeleton in glioblastoma cell lines and especially the demonstration of nestin in the nucleus represent an important background for further studies of nestin re-expression in relationship to tumor malignancy and invasive potential.
  • [MeSH-major] Glioblastoma / chemistry. Intermediate Filament Proteins / analysis. Nerve Tissue Proteins / analysis
  • [MeSH-minor] Cell Line, Tumor. Cytoskeleton / chemistry. Cytoskeleton / ultrastructure. Fluorescent Antibody Technique, Indirect. Glial Fibrillary Acidic Protein / analysis. Humans. Nestin. Vimentin / analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):503-15 [10571412.001]
  • [Cites] Exp Cell Res. 2003 Apr 1;284(2):185-95 [12651152.001]
  • [Cites] Exp Cell Res. 2000 Feb 1;254(2):269-78 [10640425.001]
  • [Cites] Mol Biol Cell. 2003 Apr;14(4):1468-78 [12686602.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(14):5090-106 [12832492.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):520-32 [14965445.001]
  • [Cites] Exp Mol Med. 2004 Feb 29;36(1):52-6 [15031671.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):27994-9 [15117961.001]
  • [Cites] J Neurosci. 1985 Dec;5(12):3310-28 [4078630.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):303-13 [1538585.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5334-41 [1382841.001]
  • [Cites] J Cell Sci. 1992 Oct;103 ( Pt 2):589-97 [1478958.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):354-6 [8275467.001]
  • [Cites] Exp Cell Res. 1994 Oct;214(2):447-58 [7925640.001]
  • [Cites] Neuron. 1994 Nov;13(5):1071-82 [7946346.001]
  • [Cites] Brain Res Dev Brain Res. 1995 Jan 14;84(1):109-29 [7720210.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):188-98 [8569181.001]
  • [Cites] Pediatr Pathol Lab Med. 1997 Nov-Dec;17(6):913-25 [9353831.001]
  • [Cites] J Struct Biol. 1997 Oct;120(1):61-8 [9356292.001]
  • [Cites] Pediatr Res. 1998 Mar;43(3):386-92 [9505279.001]
  • [Cites] Exp Cell Res. 1998 Mar 15;239(2):332-43 [9521851.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1157-68 [9777947.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):23996-4006 [10446168.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):665-71 [15736068.001]
  • [Cites] J Cell Sci. 1998 Dec 18;111 ( Pt 24):3573-84 [9819349.001]
  • [Cites] Curr Opin Cell Biol. 2000 Feb;12(1):79-90 [10679360.001]
  • [Cites] Exp Neurol. 2000 Feb;161(2):585-96 [10686078.001]
  • [Cites] Int J Dev Neurosci. 2001 Feb;19(1):101-8 [11226759.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):817-23 [11238030.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16456-63 [11278541.001]
  • [Cites] J Neurosci. 2001 Aug 15;21(16):6147-58 [11487638.001]
  • [Cites] Stem Cells. 2001;19(5):419-24 [11553850.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Exp Neurol. 2002 Mar;174(1):89-95 [11869037.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] APMIS. 2002 Jun;110(6):499-507 [12193211.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):641-55 [12209758.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):775-85 [12239616.001]
  • [Cites] Neurosci Res. 2002 Oct;44(2):207-12 [12354635.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • (PMID = 16457706.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Vimentin
  • [Other-IDs] NLM/ PMC1403792
  •  go-up   go-down


84. Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T: High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. Lancet Oncol; 2005 Dec;6(12):953-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 29 patients with anaplastic astrocytoma and 61 patients with glioblastoma who received high-dose conformal radiotherapy during 1990-2002 were compared with 34 patients with anaplastic astrocytoma and 60 patients with glioblastoma who received conventional 60 Gy radiotherapy during 1979-89.
  • 77 of the 90 patients receiving high-dose radiotherapy were given 80 Gy; the remaining 13 patients, all with glioblastoma, received 90 Gy.
  • FINDINGS: Patients who received high-dose radiotherapy had significantly longer overall survival compared with those who received conventional radiotherapy (adjusted hazard ratio 0.30 [95% CI 0.12-0.76], p=0.011 for anaplastic astrocytoma and 0.49 [0.28-0.87], p=0.014 for glioblastoma).
  • Patients with anaplastic astrocytoma in the high-dose group have not yet reached median survival; median survival in the conventional radiotherapy group was 22.3 months (95% CI 20.6-24.0).
  • Median survival in patients with glioblastoma was 16.2 months (12.8-19.6) for the high-dose group and 12.4 months (10.0-14.8) for the conventional group.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Dec;6(12):915-6 [16321754.001]
  • (PMID = 16321763.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


85. Schwartzbaum JA, Ahlbom A, Lönn S, Malmer B, Wigertz A, Auvinen A, Brookes AJ, Collatz Christensen H, Henriksson R, Johansen C, Salminen T, Schoemaker MJ, Swerdlow AJ, Debinski W, Feychting M: An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev; 2007 Nov;16(11):2448-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk.
  • In an earlier publication, using data from a Swedish case-control study, Schwartzbaum et al. report an inverse relation between risk of glioblastoma and four single nucleotide polymorphisms (SNP) on two genes [interleukin (IL)-4Ralpha, IL-13] that are associated with allergies.
  • In addition, recent studies suggest that IL-4 and IL-13 induce cyclooxygenase-2 (COX-2) to resolve brain inflammation.
  • To see whether previous Swedish results (110 cases, 430 controls) would be replicated, we estimated the association between glioblastoma and two IL-4Ralpha (rs1805015, rs1801275) and two IL-13 (rs20541, rs1800925) SNPs and their haplotypes and one COX-2 SNP (-765GC) using additional English, Danish, and Finnish data (217 cases, 1,171 controls).
  • Our data did not support our original observations relating individual IL-4Ra